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1 Liver cancer 
According to a recent report of the world health organization (WHO), primary liver 
cancer is the fifth most common cancer worldwide, which has become a serious global 
health issue [1]. The most common risk factor for hepatocellular carcinoma (HCC) was 
identified as cirrhosis of any etiology, as more than 90% of HCC patients showed a 
history of cirrhosis [2]. The underlying causes of cirrhosis are however heterogenous. 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) as well as vinyl chloride [3], smoking 
[4], aflatoxin exposure [5], and nonalcoholic steatohepatitis (NASH) [6] are all regarded 
as critical risk factors, leading to HCC heterogeneity. 
Due to the lack of sensitive and valid biomarkers for early diagnosis of HCC, the 
majority of HCC patients are diagnosed at a late stage, leaving a limited number of 
treatment options. At present, for patients detected at an early stage of tumor formation, 
tumor resection and liver transplantation are the main suitable treatment options, 
resulting in a 5-year overall survival rate of only 30%-40% [7]. For HCC patients with 
advanced disease, Sorafenib is the only treatment option, which can extend the median 
overall survival with a modest 2-3 months [8]. Therefore, it is necessary to explore the 
underlying molecular mechanisms contributing to HCC development, as they may 
provide novel treatment options.   
HCC development is a long-term multi-step process, involving a complex interplay 
between the tumor microenvironment and (epi)genetic alterations within the tumor 
cells. Throughout this stepwise progression, liver fibrosis and cirrhosis are essential 
steps toward malignancy, which among others can be provoked by chronic hepatitis 
virus infections, leading to hepatocyte apoptosis, necrosis and compensatory 
regeneration. During this long period, somatic mutations accumulate that provide 
growth advantages to the emerging tumor cells. Most frequently mutations within the 
TERT promoter (59%) are observed [9], which is recognized as an early event in HCC 
and promotes upregulation of TERT protein expression, thereby maintaining telomere 
length. Other frequently mutated genes include TP53 (10%-40%) related to HBV 
infection, CTNNB1 (20%-25%) which encodes β-catenin and appears to be more 
commonly observed with alcohol addiction or HCV infection, and AXIN1 (10%) [10, 11].  
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2 Wnt signaling pathway 
The highly conserved Wnt signaling pathway is involved in a variety of biological 
processes including homeostasis, cell proliferation, differentiation, migration and 
apoptosis [12]. The human Wnt gene family is made up of 19 members that encode 
secreted signaling proteins with 22–24 conserved cysteine residues [13]. Generally, Wnt 
signaling is subdivided in three major embranchments, that is (1) the canonical 
Wnt/β-catenin pathway, (2) the noncanonical planar cell polarity pathway, and (3) the 
noncanonical Wnt/calcium pathway. In this thesis I will mainly deal with the role of the 
Wnt/β-catenin signaling pathway and its role in liver cancer [14]. 
In this latter pathway (see Figure 1), Wnt ligands trigger cellular signal transduction 
by binding with the transmembrane receptor Frizzled (FZD) and low-density lipoprotein 
receptor-related protein 5 or 6 (LRP5/6), leading to Dishevelled(Dsh/Dvl) 
phosphorylation. Next, phosphorylated Dvl protein binds with AXIN protein, which 
inhibits GSK-3β function that is required for phosphorylation of β-catenin. As a result, 
the destruction complex consisting of the adenomatous polyposis coli (APC) tumor 
suppressor, scaffold proteins AXIN1 and AXIN2, and the kinases GSK3 and CK1α will be 
temporarily inhibited. This results in the cytoplasmic accumulation of β-catenin and 
translocation into the nucleus for binding with one of the T-cell factor/lymphoid 
enhancer-binding factor (TCF/LEF) transcription factors, ultimately leading to activation 
of target gene transcription.  
However, in the absence of Wnt ligands, within the destruction complex initially Ser45 
of β-catenin is phosphorylated by CK1α, followed by sequential GSK-3β phosphorylation 
at T41, S37 and finally S33. Next, the phosphorylated 32DpSGXXpS37 motif promotes 
binding of the ubiquitin ligase β-TrCP which targets β-catenin for proteasomal 
degradation, maintaining the free cytoplasmic β-catenin at a low level [15]. 
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Figure.1 The canonical Wnt/β-catenin signaling pathway. (A) In the absence of Wnt ligands, β-catenin is 
phosphorylated by a degradation complex consisting of GSK3β, CK1α, APC and AXIN1/AXIN2. 
Phosphorylated β-catenin is targeted for proteasomal degradation after ubiquitination by the SCF protein 
complex. (B) Activation of canonical Wnt/β-catenin signaling leads to the dissociation of the degradation 
complex. As a result, β-catenin accumulates in the cytoplasm and translocates into the nucleus, where it 
promotes the expression of target genes via interaction with TCF/LEF transcription factors and other 
proteins such as CBP, Bcl9, and Pygo. Both figure and text adapted from reference Pez F, et al [16]. 
3 Aberrant activation of Wnt/β-catenin signaling by frequently observed 
mutations in HCC   
1/β-catenin 
β-catenin encoded by the CTNNB1 gene, is the key component of Wnt/β-catenin 
signaling, and is mutated in 20-25% of HCC patients. One frequently observed 
mechanism is oncogenic β-catenin mutations containing the exon3 encoded S/T 
phosphorylation residues and β-TrCP binding motif (residues S33-S45), making the 
protein more resistant to proteolytic degradation and leading to enhanced nuclear 
signaling. However, amino-acid alterations lead to varying degrees of signaling activity. 
D32-S37 amino-acid substitutions were associated with strong activation of β-catenin 
signaling. T41 mutation resulted in a moderate activity, while S45 only weakly activated 
downstream genes.  
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Figure 2. Schematic representation of the reported binding domains of APC, AXIN, TCF/LEF and 
E-cadherin to the armadillo repeat region of β-catenin. Position of K335I and N387K mutations are
indicated by arrows. pS indicates Serine phosphorylation present at binding interface of APC or 
E-cadherin.
More recently, a new mutational hotspot region was identified in armadillo repeats 5 
and 6 of β-catenin (encoded by exons 7 and 8). Especially K335 and N387 amino acid 
alterations are commonly observed in HCC and hepatomas, and were shown to lead to a 
weak to moderate activation of the pathway [17, 18]. 
2/AXIN 
AXIN proteins were first identified in mouse. They play an important role in 
controlling embryonic development. For example, forced expression of AXIN1 in 
Xenopus oocytes inhibited dorsal-ventral axis formation. In addition, homozygous 
inactivation of Axin1 in mouse embryos, gave rise to axial duplications [21]. These 
phenotypes were reminiscent of other developmental defects observed when interfering 
with proper β-catenin signaling, which was later confirmed when AXIN’s role in the 
Chapter 1 
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β-catenin destruction complex was discovered. Nowadays AXIN proteins are regarded as 
negative regulators of Wnt signaling serving as a scaffold for the proteolytic degradation 
of β-catenin. As critical components of Wnt/β-catenin signaling, mutations in both 
AXIN1 (10%) and AXIN2 (3%) have been detected in HCC patients and cell lines [22]. 
Within AXIN1 the alterations are randomly distributed throughout most of the domains, 
including the RGS domain, the middle region and C-terminal DIX domain, which 
respectively bind with APC, GSK-3β, β-catenin, DVL and AXIN itself [23, 24]. Although 
there are no hotspot mutations in AXIN1, most mutations cause premature translational 
termination, leading to truncated proteins with loss of original function. Besides 
potentially leading to enhanced β-catenin signaling, the AXIN proteins have also been 
linked to other proteins relevant for tumorigenesis such as cMYC [25], p53 [26], TGF-β 
[27], and Smad3 signaling pathways [28].  
Originally, given its prominent role in the β-catenin destruction complex, mutational 
inactivation of AXIN1 was considered to support HCC development by aberrantly 
enhancing β-catenin signaling. This view has however been challenged in the last decade 
by several reports showing neither a clear nuclear β-catenin accumulation nor clearly 
enhanced expression of β-catenin target genes in AXIN1-mutant HCCs [29-31]. Hence, 
the extent of β-catenin signaling following AXIN1 mutation and its relevance for 
supporting HCC growth is still under debate. 
4 Identifying genes whose altered expression in HCC may promote tumor 
progression and affect patient outcome 
HCC is unusually resistant to all therapeutic interventions, and thus is associated with 
very high fatality. The reasons for the poor prognosis are mainly caused by the complex 
and variable pathogenesis and high rates of recurrence and metastasis [32, 33]. 
Generally, the 5-year overall survival rate (OS) for HCC patients with early stage disease 
is significantly higher than for patients at advanced stages [34]. Therefore, the best 
strategy for preventing liver cancer-related deaths is the early diagnosis. 
Alpha-Fetoprotein (AFP) has long been the preferred biomarker to diagnose and 
assess the prognosis for HCC patients. AFP is however not entirely specific for HCC, and 
about half of the lesions do not clearly express this marker, meaning that a big 
proportion of liver cancers cannot be faithfully identified by AFP. For these and other 
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reasons assaying AFP levels is not recommended anymore as a biomarker for HCC by the 
American and European liver disease organizations [35]. 
Hence, it is necessary to explore other differentially expressed genes to greatly 
increase the accuracy and sensitivity of early diagnosis and prognosis prediction. For 
example, Hidenari et al found that FBP1 is specifically downregulated in HCC tissues, 
which facilitated tumor progression. Meanwhile, FBP1 can also serve as a prognosis 
marker and represents a potential therapeutic target [36]. Guo et al showed that 
miR-199a-5p promotes glycolysis and has potential as a prognosis marker for HCC 
patients [37]. 
In conclusion, exploring differentially expressed genes in liver cancers has important 
value for the early diagnosis, prediction of treatment responses and prognosis 
assessment. At the same time, if the proteins encoded by these differentially expressed 
genes play important roles in the disease process, they may even become potential 
therapeutic targets and contribute to personalized treatment. 
5 The aim of this thesis 
Hepatocellular carcinoma is a global public health issue all over the world. During the 
last few decades tremendous progress has been made in treating various tumor types by 
combinations of chemotherapy, immunotherapy, and targeted therapies. Nevertheless, 
for HCC patients who are in advanced stages of their disease, the 5-year survival rate is 
still very low (<10%). Therefore, it is necessary to better understand the complex 
mechanisms contributing to liver carcinogenesis. In view of this, we focused on two main 
issues in my thesis. Given the important role played by the Wnt/β-catenin signaling 
pathway in HCC development, the first aim is to study the function of the frequently 
mutated genes CTNNB1 and AXIN1. In more detail we wish to understand how the novel 
identified mutations in the armadillo repeats 5 and 6 of β-catenin lead to enhanced 
signaling, to what extent AXIN1 mutations lead to enhanced β-catenin signaling, and to 
identify other mechanisms that may potentially affect β-catenin signaling in HCC.  
As a second aim, we wished to identify genes whose altered expression in HCC may 
promote tumor progression and affect the prognosis of patients. To this aim, we 
screened the TCGA database for genes whose altered expression correlates with survival. 
14 
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Next, candidate genes were evaluated by various in vitro assays. We identified UCK2, 
MIR324, and CEBPD as potential interesting targets of which the functional analysis of 
CEBPD is described in this thesis.  
6 Outline of this thesis 
In Chapter 1, I have reviewed how mutations within key components of the 
Wnt/β-catenin signaling pathway contribute to the progression and development of HCC, 
and described the general aim of the thesis.  
In Chapter 2, 
In Chapter 3, we show that AXIN1 inactivation leads to enhanced β-catenin signaling in 
a panel of HCC cell lines. These results question the strong statements that have been 
made in the literature, which suggest that AXIN1 mutation in liver cancer does not lead 
to increased signaling. Secondly, we show that enhancing AXIN activity by tankyrase 
monotherapy does not significantly affect their growth.  
In Chapter 4, we investigate to what extent nine HCC cell lines depend on extracellular 
Wnt secretion to support their growth. These cell lines are classified by mutations in 
either CTNNB1, AXIN1 or no obvious mutation in a β-catenin signaling related 
component.  
In Chapter 5, we found that the serine-threonine kinase receptor-associated protein 
(STRAP) protein is increased in expression in HCC tissues and regulates Wnt/β-catenin 
signaling activity in vitro.  
In Chapter 6 By analyzing the Cancer Genome Atlas (TCGA) and HCC tissue 
microarrays, we identify that CEBPD expression correlates with the prognosis of HCC 
patients. Next, we investigate its function and possible mechanism through which it 
contributes to HCC development.  
The novel insights derived from this thesis will be summarized and discussed in 
chapter 7.   
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Abstract 
Aberrant activation of Wnt/β-catenin signaling plays a key role in the onset and 
development of hepatocellular carcinomas (HCC), with about half of them acquiring 
mutations in either CTNNB1 or AXIN1. However, it remains unclear whether these 
mutations impose sufficient β-catenin signaling or require upstream Wnt ligand 
activation for sustaining optimal growth, as previously suggested for colorectal cancers. 
Using a panel of nine HCC cell lines we show that siRNA mediated knock-down of 
β-catenin impairs growth of all these lines. Blocking Wnt secretion, either by treatment 
with the IWP12 porcupine inhibitor or knockdown of WLS, reduces growth of most of 
the lines. Unexpectedly, interfering with Wnt secretion does not clearly affect the level of 
β-catenin signaling in the majority of lines, suggesting that other mechanisms underlie 
the growth suppressive effect. However, IWP12 treatment did not induce autophagy or 
endoplasmic reticulum (ER) stress, which may have resulted from the accumulation of 
Wnt ligands within the ER. Similar results were observed for colorectal cancer cell lines 
used for comparison in various assays. These results suggest that most colorectal and 
liver cancers with mutations in components of the β-catenin degradation complex do not 
strongly rely on extracellular Wnt ligand exposure to support optimal growth. In 
addition, our results also suggest that blocking Wnt secretion may aid in tumor 
suppression through alternative routes currently unappreciated. 
Keywords: Hepatocellular carcinoma; Wnt/β-catenin signaling 
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Introduction 
Hepatocellular carcinoma (HCC) is considered as the fifth most common cancer and 
the third main reason for cancer related death with 748,000 cases and 695,000 deaths 
each year [1, 2]. The etiology of HCC includes Hepatitis B virus (HBV) or Hepatitis C virus 
(HCV) infection, alcohol liver disease, non-alcoholic steatohepatitis (NASH) and 
aflatoxin-B1 exposure [3]. More than 80% of all HCCs occur in Eastern and Southeastern 
Asia where the main cause is HBV combined with exposure to aflatoxin-B1 [4]. In 
Europe, Japan and the United States, HCV represents the dominant risk factor, together 
with alcohol abuse and nonalcoholic fatty liver diseases [5, 6]. 
Wnt/β-catenin signaling plays an important role in a wide range of biological 
processes, involving embryonic patterning, cell proliferation, differentiation, 
angiogenesis, carcinogenesis, metastasis and drug resistance [7-9]. Underscoring the 
relevance of this pathway, many tumor types including HCC, exhibit enhanced 
Wnt/β-catenin signaling that strongly contributes to tumor growth [10]. Activation of 
Wnt/β-catenin signaling starts with the secretion of Wnt ligands. Wnts produced within 
the endoplasmic reticulum (ER) are palmitoylated by the Wnt acyl-transferase 
porcupine (PORCN), which is essential for their secretion and signaling activity. 
Following this lipid modification, Wntless (WLS) is needed to shuttle the Wnt proteins 
from the Golgi to the plasma membrane where they can signal in an autocrine or 
paracrine manner [11]. In the absence of upstream Wnt signaling, β-catenin is 
phosphorylated at N-terminal Ser/Thr residues by a multiprotein complex consisting of 
the adenomatous polyposis coli (APC) tumor suppressor, scaffold proteins AXIN1, AXIN2 
and AMER1, and the kinases GSK3 and CK1α. Phosphorylated β-catenin is then 
ubiquitinated, leading to its proteasomal degradation [12-14]. The overall effect is low 
β-catenin levels in the cytoplasm and nucleus of unstimulated cells.Upon binding of Wnt 
ligands to Frizzled and LRP5/6 co-receptors, Disheveled (DVL) becomes phosphorylated, 
subsequently resulting in the inhibition of the β-catenin destruction complex [15]. As a 
result, β-catenin is stabilized and is able to translocate to the nucleus and associate with 
members of the TCF/LEF family of transcription factors, thus regulating the expression 
of specific downstream Wnt/β-catenin target genes thereby affecting cellular decisions 
[4]. In addition to this classical (canonical) Wnt signaling pathway, Wnts can also signal 
in an alternative (non-canonical) fashion independent of β-catenin through associating 
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with Frizzled and ROR1/2 receptors instead of LRP5/6. Activation of non-canonical Wnt 
signaling mainly affects cellular processes involved in migration and cellular polarity [8]. 
Hepatocarcinogenesis is a multistep process, progressing from a normal hepatocyte to 
a transformed phenotype as a result of the accumulation of aberrant genetic and 
epigenetic modifications and activation of various signaling pathways [16-18]. 
Increasing evidence indicates that activation of Wnt/β-catenin signaling is critical in 
hepatic oncogenesis [19, 20]. About 40%-70% of HCCs are characterized by nuclear 
accumulation of β-catenin, the hallmark of active signaling. Various molecular and 
genetic alterations contribute to aberrant activation of Wnt/β-catenin signaling. 
Mutations within components of the canonical Wnt/β-catenin signaling enhance 
stabilization of β-catenin and transcriptional activity in the nucleus. Approximately one 
third of all HCCs carry oncogenic β-catenin mutations within exon 3 at the N-terminal 
phosphorylation residues, making the protein more resistant to proteolytic degradation 
[21]. In another subset of tumors, loss-of-function mutations of negative regulators are 
observed in the APC and AXIN1 genes, respectively in 1-3% and 8-15% of tumors [19], 
both causing compromised ability to degrade β-catenin [8]. In addition to mutations, 
various other mechanisms have been suggested to promote β-catenin signaling, 
including overexpression of Wnt ligands and/or their corresponding receptors, and 
reduced expression of extracellular inhibitors [22]. Given the importance of β-catenin 
signaling for hepatic oncogenesis, various treatments targeting this route have been 
evaluated [23]. 
Cancers harboring mutations within intracellular components of the β-catenin 
signaling pathway, i.e., mutation of APC, AXIN or β-catenin itself, were often considered 
to become largely independent of upstream regulation by extracellular Wnt ligands. This 
belief has however been challenged during the last years. For example, Wnt antagonists 
SFRPs and DKKs are reported to attenuate Wnt signaling in colorectal cancer (CRC) [24, 
25]. Recently, it was demonstrated that interfering with Wnt secretion or reducing the 
expression of specific Wnt ligands impaired the growth of APC and β-catenin mutant 
CRC cell lines [26]. These results also indicated that interfering with Wnt secretion, for 
example using the newly developed PORCN inhibitors [27, 28], could be useful as an 
additive treatment option for tumors characterized by enhanced β-catenin signaling. 
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Here, we have investigated whether this also holds truth for β-catenin or AXIN1 mutant 
liver cancer cells. 
Materials and methods 
Cell lines 
Human HCC cell lines Hep3B, Huh6, Huh7, PLC/PRF/5, SNU182, SNU398, SNU449 and 
CRC cell lines CACO2, DLD1, HT29, SW480, HCT116, LS174T, SW48 and RKO were 
cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen-Gibco, Breda, The 
Netherlands) complemented with 10% (v/v) fetal calf serum (Hyclone, Lonan, Utah), 
100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (Invitrogen-Gibco). 
The hepatoblastoma cell line HepG2 was cultured on 
fibronectin/collagen/albumin-coated plates (AthenaES) in Williams E medium 
(Invitrogen-Gibco, Breda, The Netherlands) complemented with 10% (v/v) fetal calf 
serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. HepaRG 
was cultured in William’s E medium supplemented with 10% (v/v) fetal calf serum, 100 
IU/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin (Sigma-Aldrich, St Louis, MO), 
and 50 µM hydrocortisone hemisuccinate (Sigma-Aldrich, St Louis, MO). Identity of all 
cell lines was confirmed by STR genotyping. CTNNB1 mutation status was confirmed in 
all the nine HCC cell lines by Sanger sequencing and was consistent with those reported 
at COSMIC, the Catalogue of Somatic Mutations in Cancer (http://cancer.sanger.ac.uk) 
[29]. 
For the preparation of conditioned medium, L-Control and L-Wnt3A cells were 
cultured in complete DMEM medium, followed by collection and filtration of medium 
according to standard procedures. HCC and CRC cell lines were stimulated with 25% 
L-Control or L-Wnt3A medium.
Reagents 
IWP12 (Sigma-Aldrich, St Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, St Louis, MO) with a final stock concentration of 10mM. Antibodies 
specific for β-catenin (Cat. #9561, Cell Signaling Technology), dishevelled adaptor 
protein (DVL2) (Cat. #3216, Cell Signaling Technology), WLS (Cat.#MABS87, clone YJ5 
Millipore), LC3Ⅰ /Ⅱ  (Cat. #4108, Cell Signaling Technology), GPR177(Wls/Evi) 
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(Cat.#MABS87, Millipore) and β-actin (sc-47778, Santa Cruz), Tubulin (sc-8035, Santa 
Cruz) anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (Stressgen, 
Glandford Ave, Victoria, BC, Canada) were used for western blot analysis. 
Table1. Gene mutations of Wnt/β-catenin signaling components in HCC and CRC cell lines 
Cell line Gene AA alteration Zygosity 
HCC 
HepG2 CTNNB1 p.W25_I140 del Heterozygous 
Huh6 CTNNB1 p.G34V Heterozygous 
SNU398 CTNNB1 p.S37C Heterozygous 
Hep3B AXIN1 p.R146* Homozygous 
PLC/PRF/5 AXIN1 p.(R373_M418 del) Homozygous 
SNU449 AXIN1 p.R712* Homozygous 
Huh7    
HepaRG    
SNU182    
CRC 
SW480 APC p.Q1338* Homozygous 
HT29 APC p.T1556fs*3 Heterozygous 
  p.E853* Heterozygous 
Caco2 APC p.Q1367* Homozygous 
DLD1 APC p.R2166* Heterozygous 
  p.I1417fs*2 Heterozygous 
 AXIN1 p.L396M Heterozygous 
 RNF43 p.G659fs*41 Heterozygous 
SW48 CTNNB1 p.S33Y Heterozygous 
 RNF43 p.G659fs*41 Heterozygous 
  p.V299fs*143 Heterozygous 
HCT116 CTNNB1 p.S45del Heterozygous 
 RNF43 p.R117fs*41 Heterozygous 
LS174T CTNNB1 p.S45F Homozygous 
RKO RNF43 p.G659fs*41 Heterozygous 
Gene knockdown by small interfering RNA (siRNA) 
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Smartpool ON-TARGETplus siRNAs targeting CTNNB1 and WLS were obtained from 
Dharmacon. The ON-TARGETplus Non-targeting siRNA #2 was used as negative control. 
Cells were reverse-transfected in a 96-well plate using a total of 0.2 ul DharmaFECT 
formulation 4 (Thermo Fischer Scientific) and 25nM of each siRNA per well. Following 
72 hours incubation, the effect on knock-down was determined by western blotting. 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). CDNA 
was prepared from total RNA using a cDNA Synthesis Kit (TAKARA BIO INC) and 
subjected to quantitative Real-Time PCR analyses. Analyses were performed using the 
StepOne Real-Time PCR System and the StepOnev2.0 software (Applied Biosystem, 
Darmstadt, Germany). Primer sequences are provided in supplementary Table1. All 
expression levels are depicted relative to the expression of GAPDH. 
Western blot assay 
Cells were lysed in Laemmli sample buffer with 0.1 M DTT and heated for 5-10 
minutes at 95 ℃, followed by loading and separation on a 8-15% sodium dodecyl 
sulphate-polyacrylamide gels (SDS-PAGE). After 90 min running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane 
(Invitrogen) for 1.5 h with an electric current of 250 mA. Subsequently, the membrane 
was blocked with 2.5 ml Odyssey Blocking Buffer and 2.5 ml PBS containing 0.05% 
Tween 20 (PBS-T), followed by incubation with primary antibody (all 1:1000) overnight 
at 4 °C. The membrane was washed 3 times with PBS-T followed by incubation for 1.5 h 
with anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (LI-COR 
Biosciences, Lincoln, USA) (1:5000) at room temperature. Blots were assayed for β-actin 
or Tubulin content as standardization of sample loading, scanned, and quantified by 
Odyssey infrared imaging (Li-COR Biosciences, Lincoln, NE, USA). Results were 
visualized and quantified with Odyssey 3.0 software. 
β-catenin reporter assays 
The β-catenin reporter assays were basically performed as previously described [30, 
31]. In short, twenty hours before transfection, we plated 105 cells per well on 12-well 
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plates. Each well was transfected with 500 ng Wnt Responsive Element (WRE) or 
Mutant Responsive Element (MRE) vectors and 20 ng TK-Renilla using polyethylenimine 
(PEI) (Sigma-Aldrich, St Louis, MO) or Fugene HD (Promega). We measured luciferase 
activities in a LumiStar Optima luminescence counter (BMG LabTech, Offenburg, 
Germany) and normalized the data for the transfection efficiency by using the Dual 
Luciferase Reporter Assay system (Promega) according to the manufacturer’s 
instruction. Transfections were performed in triplicate and the mean and standard error 
were calculated for each condition. The β-catenin reporter activities are shown as 
WRE/MRE ratios. 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) 
was added to cells seeded in 96-well plates and incubated at 37°C with 5% CO2 for 3 h. 
The medium was removed and 100 µl DMSO was added to each well. The absorbance of 
each well was read on a microplate absorbance reader (BIO-RAD) at wavelength of 490 
nm. For siRNA mediated knockdown of genes, 4 independent wells were assayed for 
each cell line at least two times, whereas for IWP12 treatment 6 independent wells were 
used. The mean and standard error were calculated for each condition. 
Cell cycle analysis 
Around 60%-80% confluency, cells were trypsinized and washed with PBS and then 
fixed in cold 70% ethanol overnight at 4℃. The cells were washed twice with PBS and 
incubated with 20ug/ml RNase at 37°C for 30 min followed by incubation with 50ug/ml 
Propidium Iodide (PI) at 4°C for 30min. Then samples were tested immediately by FACS. 
Cell cycle was analyzed by FlowJo_V10 software. For each treatment, two independent 
wells were tested for Huh6, SNU449 and Huh7 two times. The mean and standard error 
were calculated for each condition. 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were 
performed with one sample t test. Differences were considered significant at a p value 
less than 0.05. 
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Results 
β-catenin signaling activity of HCC cell lines 
To investigate the importance of β-catenin signaling and Wnt secretion for sustaining 
cell growth, we employed 9 HCC cell lines, listed in Table 1 in which gene mutations 
related to Wnt/β-catenin signaling are depicted. We also used 8 CRC cell lines for 
comparison in various assays, known to largely depend on β-catenin signaling for their 
growth. First, we determined the baseline β-catenin signaling activity for all these cell 
lines using a β-catenin reporter assay and qRT-PCR of AXIN2, a well-established 
β-catenin target gene. As indicated in Figure 1, in line with previous publications, all 
β-catenin mutant HCC lines (SNU398, HepG2 and Huh6) showed a robust induction of 
both reporter activity as well as high AXIN2 expression. The AXIN1 mutant lines 
(PLC/PRF/5, Hep3B and SNU449) also displayed enhanced reporter activity, albeit 
generally more modest, whereas the expression of AXIN2 was low. Interestingly, among 
the HCC lines without an obvious mutation, SNU182 presented with high β-catenin 
signaling activity, both on reporter level and AXIN2 expression. Huh7 and HepaRG 
showed low reporter activity together with low AXIN2 expression. All CRC lines, except 
RKO being wild type for APC and CTNNB1, showed the expected increase in reporter 
activity (Figure S1). 
 
Fig.1. Baseline β-catenin signaling activity in HCC cell lines. (A) β-catenin luciferase reporter assay 
showing β-catenin signaling activity in HCC cell lines (mean ± SD, n = 3). The β-catenin reporter activities 
are depicted as WRE/MRE ratios. (B) QRT-PCR assay showing expression of the β-catenin target gene 
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AXIN2 in HCC cell lines (mean ± SD, n = 3). Expression levels are depicted relative to the housekeeping 
gene GAPDH. 
Requirement for β-catenin signaling to sustain efficient cell growth 
Next, we determined the dependence on β-catenin signaling for supporting efficient 
growth by transiently transfecting smartpool siRNAs targeting CTNNB1 or a control 
siRNA, followed by a MTT assay to test cell numbers after 3 days of culture. For most cell 
lines we accomplished more than 80% knock-down of β-catenin at protein level as 
determined by quantitative western blot analysis, with the exception of HepaRG in 
which a 65% reduction was observed (see Figures 2A and S2). As indicated in Figure 2B, 
β-catenin signaling activity was clearly suppressed by siRNA mediated knockdown in 
the three lines tested for this purpose, i.e. Huh6, SNU449 and Huh7. All HCC cell lines 
were inhibited significantly in their growth (Figure 2C) suggesting that β-catenin 
signaling is important for the growth of these tumor cells, even in the ones that show 
only low to modest levels of signaling, such as Huh7 and HepaRG. Cell cycle analysis in 
three lines showed that β-catenin knockdown provoked a dramatic G0/G1 phase arrest 
in Huh6 (Fig 2D). Also in Huh7 a notable increase of cells in G0/G1 is observed with a 
significant reduction of cells in the G2/M phase, whereas for SNU449 a trend is observed 
towards more cells in G0/G1 and less cells in S-phase. As expected, all five tested CRC 
cell lines showed a significantly reduced growth upon β-catenin knockdown (Figure 2E). 
Expression levels of WNT ligands in HCC cell lines 
Taken together, the results above indicate that targeting the β-catenin signaling 
pathway represents an attractive route to suppress the growth of HCCs. This pathway 
has however been refractory to target in an efficient manner. More recently, inhibitors 
of Wnt secretion have been proposed as treatment options for malignancies dependent 
on Wnt-ligand secretion for their growth [26-28]. However, a prerequisite is that the 
tumor cells express sufficient levels of Wnt ligands capable of inducing β-catenin 
signaling. Hence, we investigated the expression profile of all 19 Wnt ligand genes in our 
HCC cell line panel by qRT-PCR. From the group of Wnt ligands more commonly 
associated with inducing β-catenin signaling (WNT1, 2, 3, 3A, 8A, 8B, 10A and 10B), only 
WNT3 was clearly expressed in all HCC cell lines, followed by high WNT10A expression 
restricted to the SNU182 and HepaRG cell lines, and high WNT2 expression in SNU449 
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(Figure 3A). The remaining ligands of this group are barely detectable or expressed at 
least at 10-fold lower levels in all cell lines (Figure S3). When piling up the expression of 
all Wnt ligands from this group (Figure 3B), the SNU182 cell line clearly stands out as 
one with overall highest expression level, which may explain its high β-catenin signaling 
activity reported above. The β-catenin and AXIN1 mutant cell lines are among the 
low-to-intermediate ones. 
Among the group of Wnt ligands more commonly associated with activating 
alternative pathways (WNT4, 5A, 5B, 6, 7A, 7B and 11) depicted in Figure S4A, WNT5A 
was most prominently expressed, being very high in HepaRG and SNU182, and readily 
detectable in SNU398 and SNU449. The latter cell line also shows high expression of 
WNT5B and WNT7B. Other Wnt ligands of this group are detectable only at low levels or 
absent within 
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Fig.2. Requirement of β-catenin signaling for sustaining HCC cell growth. (A) HCC cell lines were 
transiently transfected with CTNNB1 siRNAs for 72 hours. Cell lysates were collected for western blotting 
with indicated antibodies. Tubulin and β-actin served as loading control (LC). (B) Silencing of β-catenin 
caused the reduction of β-catenin signaling activity (mean ± SD, n=2, two times). (C) Silencing of β-catenin 
inhibited the growth of HCC cell lines as determined by MTT assay (mean ± SD, n=4, two times). (D) 
Silencing of β-catenin alters cell cycle progression in Huh6 (all phases significantly changed) and Huh7 
cells (G2/M phase significantly reduced). SNU449 is less clearly altered, although the proportion of cells in 
S-phase is reduced (mean ± SD, n=2, two times). (E) β-catenin knockdown reduced cell growth in 
colorectal cancer cell lines. Values depicted are relative to the ones obtained with the non-targeting siRNA 
that are arbitrarily set to 1. *p<0.05; **p<0.01. 
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Most cell lines. Overall, SNU182 is again the most prominent expressing cell line, 
whereas the β-catenin and AXIN1 mutant cell lines are among the low-to-intermediate 
expressers (Figure 3B). Of the remaining Wnt ligands (WNT2B, 9A, 9B and 16), WNT2B 
was highly expressed in PLC/PRF/5, SNU182, SNU398, and SNU449, while WNT9B was 
clearly expressed in Hep3B (Supplemental Figure S4B). 
Combining the expression of all Wnt ligands shows that SNU182 has again the highest 
overall levels, followed by HepaRG and SNU449 (Figure 3B, right panel). As all Wnt 
ligands trigger the phosphorylation of DVL2 upon binding of either the FZD_LRP5/6 or 
FZD_ROR1/2 receptor complexes [32, 33], we determined baseline pDVL2 levels in all 
cell lines. As shown in Figure 3C, highest levels of phosphorylated DVL2 are observed in 
the three cell lines with highest Wnt levels, whereas for the remaining six lines no clear 
correlation can be observed. 
 
Fig.3. Expression levels of Wnt family members in HCC cell lines determined by qRT-PCR. (A) Expression 
levels of the top three expressed “canonical” Wnt ligands (mean ± SD, n=3). (B) Piled-up expression levels 
of canonical, non-canonical and overall Wnt ligands, respectively. All expression levels are depicted 
relative to the housekeeping gene GAPDH. (C) Baseline levels of phosphorylated DVL2 (pDVL2) in all HCC 
cell lines. Values below the image represent percentage of total DVL2 that is in the phosphorylated form 
(upper band). 
Chapter 4  
 
96 
 
In summary, although all HCC cell lines show a large variation in Wnt ligand 
expression, they all express Wnt ligands that can contribute to β-catenin signaling. 
Wnt secretion blockage reduces growth of HCC cells 
Given that most HCC cell lines show increased β-catenin signaling activity and 
expression of canonical Wnt ligands, we wished to investigate the consequences of 
suppressing the secretion of Wnt ligands. To this aim we used two methods, i.e., 
treatment with IWP12, an effective inhibitor of PORCN required for palmitoylation of 
Wnt proteins [34], and knockdown of WLS, which shuttles the palmitoylated Wnts from 
the Golgi to the plasma membrane. Both treatments are expected to reduce overall levels 
of secreted Wnt ligands. Following three days of IWP12 treatment, reduced cell numbers 
were observed for all β-catenin mutant cell lines (Figure 4A), ranging from 10% 
reduction (Huh6) to 35% (SNU398). Among the non-mutant lines, growth of HepaRG 
was strongly suppressed by IWP12, whereas Huh7 and SNU182 showed more modest 
reductions of their growth. The AXIN1 mutant lines were not clearly affected by IWP12 
with the exception of PLC/PRF/5. Effects on growth following knockdown of WLS were 
largely in line with IWP12 treatment, with the exception of the AXIN1 mutant lines 
Hep3B and SNU449 that were significantly suppressed by WLS knockdown, and a less 
impressive growth reduction of HepaRG when compared with IWP12 (Figure 4B). 
Examples of efficient WLS knockdown are shown in supplemental Figure S5. 
For comparison, the same assays were also performed on five CRC cell lines (Figure 
4C, D). Both treatments showed the strongest growth suppression when applied to the 
β-catenin and RNF43 mutant HCT116 cell line. Intermediate effects were observed in 
DLD1, HT29, and SW480, whereas CACO2 was barely affected. In conclusion, most HCC 
and CRC cell lines are suppressed in their growth by both IWP12 treatment as well as 
WLS knockdown. 
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Fig.4. Inhibition of growth by Wnt secretion blockage. (A, C) IWP12 reduced cell growth of most HCC and 
CRC cell lines. Cell lines were incubated with 5 µM IWP12 for 72 hours and tested by MTT assay (mean ± 
SD, n=6, two times). Values depicted are relative to cell numbers obtained with the control DMSO 
treatment that are set to 1. (B, D) Cell lines were transiently transfected with WLS or non-targeting siRNAs 
for 72 hours, followed by MTT assay (mean ± SD, n = 4, two times). Values depicted are relative to cell 
numbers obtained with the non-targeting siRNA that are set to 1. *p<0.05; **p<0.01.
Altered exposure to extracellular Wnt ligands does not affect β-catenin signaling 
activity in most HCC cell lines 
Previously, it was reported that Wnt secretion is required to maintain sufficiently high 
levels of canonical Wnt/β-catenin signaling activity in both APC and β-catenin mutant 
CRC cell lines [26]. Here, we asked whether the β-catenin and AXIN1 mutant HCC cell 
lines were also dependent on Wnt secretion to sustain this pathway activity. Exposure to 
extracellular Wnt ligands was again reduced by treating all cell lines with IWP12, after 
which we measured β-catenin signaling activity using the reporter assay and AXIN2 
qRT-PCR. After 48 hours, β-catenin reporter activity was clearly suppressed only in 
SNU182 (Figure 5A), whereas the remaining eight HCC lines were not or only modestly 
inhibited in their reporter activity. Reduction of AXIN2 expression confirmed the strong 
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repressing effect of IWP12 in the SNU182 cell line, while no reduction was observed in 
the other cell lines (Figure 5B). Overall, this analysis shows that IWP12 treatment barely 
affects β-catenin signaling activity in most HCC cell lines, with the exception of SNU182. 
In a true tumor setting, in addition to autocrine signaling, HCC cells are also exposed 
to Wnt ligands coming from the tumor microenvironment. Therefore, to determine the 
effects on β-catenin signaling of increased levels of extracellular Wnt ligands, we 
exposed them to L-Wnt3A conditioned medium. As shown in Figure 5C, β-catenin 
reporter activity was strongly enhanced in the Huh7 cell line and clearly activated in 
SNU182, both of which were confirmed by qRT-PCR for AXIN2 (Figure 5D). Importantly, 
none of the β-catenin or AXIN1 mutant HCC lines showed enhanced β-catenin signaling 
following the addition of L-Wnt3A conditioned medium. 
These results indicate that β-catenin and AXIN1 mutant HCC cell lines appear largely 
insensitive to the level of Wnt ligand exposure for sustaining intracellular β-catenin 
signaling, which could either mean that the expressed mutant β-catenin or AXIN1 
protein determine overall signaling levels in a dominant fashion or, alternatively, that 
these cells have defects in their machinery to transduce Wnt signals. To test the latter 
option, we determined pDVL2 levels following treatment with IWP12 or L-Wnt3A 
conditioned medium (Figure 5E). Phosphorylation levels were not changed in Huh6, and 
only a modest reduction was observed in HepG2 following IWP12 treatment. In contrast, 
the SNU398 cell line showed a robust response in pDVL2 levels, decreasing from 21% to 
7% by IWP12 treatment and upregulation to 59% following Wnt3A treatment. Thus, 
both options may hold true depending on the specific cell line under investigation. High 
variability in pDVL2 response was also observed in the remaining AXIN1-mutant and 
non-mutant HCC cell lines. The PLC/PRF/5 cell line showed a low baseline pDVL2 level, 
which was altered neither by IWP12 nor Wnt3A. The Huh7 and Hep3B cell lines also 
showed low baseline levels, which can however clearly be increased by the addition of 
Wnt3A. On the other hand, most DVL2 was phosphorylated at baseline in SNU182, which 
can be inhibited by IWP12, but can hardly be further stimulated by the addition of 
Wnt3A. Lastly, SNU449 and HepaRG showed intermediate pDVL2 levels at baseline that 
can both be reduced and activated by the respective treatments. Thus, all HCC cell lines 
show a large variation in both their baseline levels of pDVL2 as well as responsiveness 
to Wnt ligand exposure, irrespective of their mutation status. 
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Fig.5. Growth reduction due to decreased Wnt secretion appears independent from β-catenin signaling. (A) 
β-catenin reporter activity was not clearly reduced by IWP12 in most HCC cell lines, except for SNU182 
(mean ± SD, n=3). (B) QRT-PCR for AXIN2 showed that its expression following IWP12 treatment was only 
reduced significantly in the SNU182 cell line (mean ± SD, n=3, two times). (C) L-Wnt3A conditioned 
medium significantly promoted β-catenin signaling activity in Huh7 and SNU182 cell lines. A significant 
albeit modest reduction of reporter activity was observed in HepG2. (mean ± SD, n=3). (D) Increased 
β-catenin signaling in SNU182 and Huh7 following L-Wnt3A treatment was confirmed by AXIN2 qRT-PCR 
(mean ± SD, n=3, two times). All qRT-PCR and reporter values are depicted relative to the numbers 
obtained for the controls, which are arbitrarily set to 1. *p<0.05; **p<0.01. (E) Phosphorylation level of 
DVL2 protein following treatment with IWP12 or L-Wnt3A conditioned medium (“Con” is DMSO only, 
“L-Con” is L-Control conditioned medium). Values below the images represent percentage of total DVL2 
that is in the phosphorylated form (upper band).
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Response of CRC cell lines to alterations in Wnt ligand levels 
Among the eight CRC cell lines treated with IWP12, only HCT116 showed a significant 
reduction in β-catenin reporter activity as well as AXIN2 expression (Figure 6A,B). 
AXIN2 expression was slightly reduced in HT29 and SW480, while CACO2 showed a 
reduced reporter activity only. Interestingly, HCT116 was also the only cell line in which 
both reporter activity and AXIN2 expression could be significantly stimulated by the 
addition of extracellular Wnt3A (Figure 6C,D). Analysis of pDVL2 levels in a selection of 
5 CRC lines showed that overall baseline levels were low with the exception of HCT116 
in which 60% of DVL2 is phosphorylated (Figure 6E). IWP12 treatment shows the 
expected decrease in pDVL2 in HCT116, whereas none of the other cell lines showed 
clear alterations in pDVL2 levels following treatment with either IWP12 or Wnt3A. 
 
Blocking Wnt secretion reduces growth of HCC 
 
101 
 
Fig.6. Responsiveness of CRC cell lines to alterations in Wnt ligand levels. (A) β-catenin reporter activity 
was significantly reduced by IWP12 in CACO2 and HCT116 cell lines (mean ± SD, n=3). (B) QRT-PCR for 
AXIN2 showed that IWP12 treatment reduced its expression in HCT116. Modest but significant reductions 
were observed in HT29 and SW480 cell lines (mean ± SD, n=3, two times). (C) L-Wnt3A conditioned 
medium only increased β-catenin reporter activity significantly in HCT116 (mean ± SD, n=3).(D) AXIN2 
qRT-PCR confirmed upregulation of β-catenin signaling due to L-Wnta3A in HCT116. Significant but 
modest increases in AXIN2 expression are seen in SW48 and DLD1 (mean ± SD, n=3). Reporter values are 
depicted relative to the numbers obtained for the controls, which are arbitrarily set to 1. *p<0.05; 
**p<0.01. (E) Top image shows comparison of baseline pDVL2 levels within a selection of five CRC cell 
lines. Bottom images show pDVL2 levels following treatment with IWP12 or L-Wnt3A conditioned 
medium (“Con” is DMSO only, “L-Con” is L-Control conditioned medium). Values below the images 
represent percentage of total DVL2 that is in the phosphorylated form (upper band). 
Blocking Wnt secretion does not lead to increased ER stress 
Blocking Wnt secretion using IWP12 or WLS knockdown reduces growth of HCC cell 
lines, apparently largely independent of β-catenin signaling. These treatments however 
also predict the accumulation of Wnt ligands in the ER, which may lead to activation of 
an ER stress response thereby reducing proliferation or inducing apoptosis. Therefore, 
ER stress was evaluated after IWP12 treatment in HCC cell lines using the expression of 
the ER-stress induced genes CHOP and GRP94 as a read-out. As shown in Figure 7A and 
7B, expression of CHOP was clearly increased in SNU398 (4.5-fold), whereas GRP94 
expression was elevated in SNU182 (2.8-fold). However, none of the other HCC cell lines 
displayed strong signs of induction. Overall, these results suggest that blocking Wnt 
secretion is not associated with the induction of a strong ER stress response. 
Chapter 4  
 
102 
 
 
Fig.7. IWP12 treatment does not lead to the induction of a strong ER stress response or autophagy. 
Following 48 hours of IWP12 treatment, the expression of the ER stress induced response genes CHOP (A) 
and GRP94 (B) was evaluated by qRT-PCR (mean ± SD, n=3). Except for a clear induction of CHOP in 
SNU398 and GRP94 in SNU182, IWP12 caused slight or no induction of an ER stress response in other cell 
lines. Values depicted are relative to those obtained for the untreated control samples that are arbitrarily 
set to 1. *p<0.05; **p<0.01. (C) Wnt secretion inhibition does not enhance autophagy in HCC cell lines. 
After incubation with IWP12 for 48 hours, the expression of LC3-Ⅱwas tested by western blot. 
Wnt secretion inhibition does not induce autophagy 
Since knockdown of β-catenin or suppression of β-catenin signaling induced 
autophagy and even autophagic cell death in head and neck squamous cell carcinoma 
cells [35] and breast cancer stem-like cells [36], we further hypothesized that blocking 
Wnt secretion could exert similar effects on HCC cell lines. During autophagy the 
microtubule-associated protein 1A/1B-light chain 3 (LC3) is converted through 
lipidation into a lower migrating isoform (LC3-II) detectable by western blot, which is 
used as an indicator of autophagosome formation. As indicated in Figure 7C, IWP12 
treatment does not change the LC3 pattern in any of the HCC cell lines, showing that it 
does not induce autophagy. 
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Discussion 
In this article we have investigated the importance of β-catenin signaling and Wnt 
secretion for sustaining hepatocellular carcinoma growth. Using a panel of 9 HCC cell 
lines we show that β-catenin signaling is required to support optimal growth in all of 
them, in line with other reports using a limited number of cell lines [37, 38]. This is to be 
expected for cell lines carrying oncogenic β-catenin mutations in which the activating 
mutation will have provided a selective growth advantage during tumor formation, but 
it also holds true for the non-mutant ones that show only low levels of baseline signaling, 
such as Huh7 and HepaRG, as well as the AXIN1 mutant lines. The latter observation is of 
relevance as it has been debated whether AXIN1 mutations lead to a significant 
enhancement of β-catenin signaling within liver cancers. This subset of tumors 
apparently lacks a robust nuclear β-catenin accumulation and shows no clear 
upregulation of target genes such as AXIN2 or GLUL [39, 40]. Also in our hands, the 
AXIN1 mutant lines are among the lowest expressors of AXIN2. Nevertheless, in these 
lines AXIN2 was readily detectable by qRT-PCR (Ct values below 28), in addition to 
β-catenin reporter activities approaching those of the β-catenin mutant ones. Given that 
also these lines are suppressed in their growth following β-catenin knockdown, it shows 
that the majority of HCCs independent of their mutational profile, rely on β-catenin 
signaling for optimal growth. 
Besides its role in signaling, β-catenin is also involved in cell-cell adhesion by directly 
binding to cadherins [41]. As such, the siRNA mediated knock-down that we apply here, 
will also likely reduce the amount of β-catenin sequestered at these adherens junctions. 
However, several investigations have shown that complete loss of β-catenin does not 
automatically lead to alterations in cell adhesion, including hepatocytes and 
hepatocellular cancer cells [42-45]. In all cases, it was shown that ɣ-catenin 
compensates for its loss, thereby retaining normal cell adhesion. Importantly, these 
studies show that it is mainly the signaling function of β-catenin that is affected 
following knock-down. 
Next we addressed the question to what extent extracellular exposure to Wnt ligands 
contributes to the observed levels of β-catenin signaling. Using qRT-PCR we tested the 
expression of all 19 Wnt ligands in our cell line panel. The Wnt expression profile that 
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we observed largely corresponds with the semi-quantitative analyses performed by 
others [22, 46]. WNT3 is the most abundantly expressed “canonical” Wnt ligand 
uniformly expressed in all cell lines, whereas all the others are expressed at low level or 
only in a subset of the cell lines. SNU182 clearly stands out as the overall highest 
expressor of Wnt ligands, likely explaining the high level of phosphorylated DVL2 that 
we observed in this cell line [33]. Among the non-mutant lines, SNU182 also showed the 
highest β-catenin reporter activity and level of AXIN2 expression, comparable with the 
β-catenin mutant ones. As such, it is not unexpected that this cell line strongly relies on 
Wnt ligand secretion to retain increased β-catenin signaling. In fact, it is the only HCC 
cell line that shows a clear reduction following Wnt secretion blockage on both reporter 
activity as well as AXIN2 expression level. On the other hand, the non-mutant Huh7 cell 
line expresses the lowest amount of Wnt ligands explaining its low baseline signaling 
levels, but it is highly responsive to Wnt ligand exposure for inducing strong β-catenin 
signaling. Within a true tumor setting it may represent a subtype of liver cancers that 
heavily depends on Wnt ligands expressed by cells within the tumor microenvironment, 
whose secretion would also be inhibited by the porcupine inhibitors employed here, 
whereas the SNU182 line is largely autonomous in this respect. Importantly, none of the 
β-catenin and AXIN1-mutant HCC cell lines are clearly affected in β-catenin signaling 
upon alterations in Wnt ligand exposure, irrespective of their source, suggesting that the 
expressed oncogenic β-catenin or mutant AXIN1 proteins determine overall signaling 
levels in a dominant fashion. 
In our hands this also holds true for most of the APC and β-catenin mutant CRC lines 
that we investigated. Among 8 CRC lines tested, only HCT116 shows a strongly reduced 
reporter activity and AXIN2 levels following IWP12 treatment, while it is also the only 
one in which both β-catenin signaling readouts are clearly increased after Wnt3A 
exposure. Analysis of pDVL2 levels is largely in accordance with this lack of response, i.e. 
most cell lines tested show only low baseline levels that are barely changed by either 
treatment (DLD1, HT29, SW480), suggesting that these lines are not actively signaling 
through Wnt ligand receptors. These results also challenge the universal validity of the 
conclusions drawn by Voloshanenko et al. who proposed that colorectal cancers still 
strongly depend on Wnt ligand exposure for maintaining optimal β-catenin signaling 
levels [26]. Their overall well-performed study depended on a thorough analysis of the 
HCT116 cell line and to a lesser extent on other lines such as DLD1. Importantly, the 
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β-catenin mutant HCT116 cell line is nowadays known to carry an inactivating mutation 
in the transmembrane E3 ubiquitin ligase RNF43, which strongly sensitizes these cells to 
exposure by Wnt ligands (see discussion below) [28, 47-49]. As such, their study may 
have unknowingly overstated the importance of Wnt ligand signaling for CRC growth in 
general, warranting a more extensive analysis in a larger cohort of CRC samples and cell 
lines. 
In recent years, Wnt secretion inhibitors, such as the porcupine inhibitor used in our 
study, have emerged as candidate drugs for treating Wnt-driven cancers. Cancers that 
are considered to be especially responsive to these treatments are the ones carrying 
somatic mutations resulting in a persistent presence of Wnt receptors at the cell surface 
[28, 48]. In normal cells, the Wnt/Frizzled receptors are continuously endocytosed and 
degraded following ubiquitination by RNF43 or its close homolog ZNRF3. Both these 
ubiquitin ligases are inhibited in their action by one of four secreted R-spondin proteins 
[50]. Consequently, mutational inactivation of RNF43/ZNRF3 or a strongly increased 
production of R-spondins through the generation of aberrant fusion transcripts, both 
lead to tumor cells with high levels of Wnt/Frizzled receptor at their surface and 
hyper-responsiveness to Wnt ligands. These genetic aberrations have been identified in 
10-20% of CRCs and in various other tumor types [28, 51, 52], but are to the best of our 
knowledge not present in HCCs, suggesting that these tumors are not prime candidates 
for treatment with Wnt secretion inhibitors. Nevertheless, our analysis shows that most 
of the HCC cell lines are reduced in their growth to varying extents, following both WLS 
knockdown as well as IWP12 treatment. 
The mechanism of the growth suppression remains more elusive at present. Except 
for the SNU182 cell line, we do see little evidence of β-catenin signaling modulation, 
suggesting that other mechanisms are at play. One possibility is the induction of ER 
stress resulting from the aberrant accumulation of Wnt ligands in the ER. However, 
except from increased expression of the ER-induced genes CHOP and GRP94, in resp. 
SNU398 and SNU182, we do not see strong evidence that Wnt secretion blockage leads 
to high levels of ER stress. In addition, autophagy did not contribute to the growth 
suppression either as there was no visible change in the pattern of the autophagy 
marker LC3 following IWP12 treatment. An alternative explanation may reside in the 
reduced secretion of Wnt ligands more commonly signaling through β-catenin 
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independent pathways. Activation of these alternative pathways has however mainly 
been shown to affect cellular processes involved in migration and cellular polarity and 
actually to counteract cell proliferation [8]. This “non-canonical” pathway has not been 
extensively studied in liver cancer, but the available literature does indeed support a 
growth suppressive effect [46, 53]. Therefore, interfering with the secretion of this 
subset of Wnt ligands is expected to support cellular growth, which is in contrast to the 
growth suppression that we observe. In line with our results, Covey et al. have shown 
that knocking-down PORCN in various tumor cell lines reduced their growth through a 
Wnt-independent pathway [54]. Also in their case no obvious explanation could be 
uncovered, but both studies highlight the importance of considering alternative roles for 
proteins involved in Wnt secretion and their role in regulating cell growth. 
In conclusion, our study shows that the majority of HCC cell lines depend on β-catenin 
signaling for maintaining optimal growth. Extracellular exposure to Wnt ligands has a 
minor contribution to overall β-catenin signaling strength in the β-catenin and 
AXIN1-mutant cell lines. Despite this observation, interfering with Wnt secretion 
through WLS knockdown or inhibition of porcupine function results in reduced growth, 
indicating that these proteins may have alternative roles currently unappreciated. 
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Supplementary Figures and Tables 
Fig.S1. Wnt/β-catenin signaling activity in CRC cell lines determined by a β-catenin luciferase reporter 
assay (mean ± SD, n=3). 
Fig.S2. SiRNA mediated silencing of β-catenin in CRC cell lines confirmed by western blotting. 
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Fig.S3. Expression levels of remaining “canonical” Wnt ligands in HCC cell lines tested by qRT-PCR (mean 
± SD, n =3). 
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Fig.S4. Expression levels of “non-canonical” (A) and unclassified (B) Wnt ligands in HCC cell lines tested by 
qRT-PCR (mean ± SD, n =3). 
 
Fig.S5. SiRNA mediated silencing of WLS in HCC cell lines tested by western blotting.  
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Abstract 
Aberrant activation of Wnt/β-catenin signaling plays a key role in the onset and 
development of hepatocellular carcinomas (HCC), with about half of them acquiring 
mutations in either CTNNB1 or AXIN1. The serine/threonine kinase receptor-associated 
protein (STRAP), a scaffold protein, was recently shown to facilitate the aberrant 
activation of Wnt/β-catenin signaling in colorectal cancers. However, the function of 
STRAP in HCC remains completely unknown. Here, increased levels of STRAP were 
observed in human and mouse HCCs. RNA sequencing of STRAP knockout clones 
generated by gene editing of Huh6 and Huh7 HCC cells revealed a significant reduction 
in expression of various metabolic and cell-cycle–related transcripts, in line with their 
general slower growth observed during culture. Importantly, Wnt/β-catenin signaling 
was impaired in all STRAP knockout/down cell lines tested, regardless of the underlying 
CTNNB1 or AXIN1 mutation. In accordance with β-catenin's role in (cancer) stem cell 
maintenance, the expressions of various stem cell markers, such as AXIN2 and LGR5, 
were reduced and concomitantly differentiation associated genes were increased. 
Together, these results show that the increased STRAP protein levels observed in HCC 
provide growth advantage among others by enhancing Wnt/β-catenin signaling. These 
observations also identify STRAP as a new player in regulating β-catenin signaling in 
hepatocellular cancers. 
 
 
 
 
 
Keywords: Hepatocellular carcinoma, STRAP, Wnt/β-catenin signaling, tissue 
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Introduction 
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third 
leading cause for cancer related deaths worldwide with around 500,000 new cases 
diagnosed each year (1, 2). Hepatocarcinogenesis initiates with the accumulation of 
aberrant genetic and epigenetic modifications leading to the dysregulation of signaling 
pathways, which transform the normal hepatocytes towards malignant phenotypes (3). 
Inappropriate activation of Wnt/β-catenin signaling has been frequently reported in 
HCC (4). As the central component of Wnt/β-catenin signaling, the transcription factor 
β-catenin is tightly regulated by a multiprotein complex composed of the adenomatous 
polyposis coli (APC) tumor suppressor, scaffold proteins AXIN1, AXIN2 and the kinases 
GSK3 and CK1α (4, 5). In the absence of Wnt ligands, β-catenin is constitutively 
phosphorylated and degraded to maintain a minimal level in the cytoplasm. On Wnt 
stimulation, the multiprotein complex dissociates causing the accumulation of cytosolic 
and nuclear β-catenin. The latter triggers the transcription of specific target genes. 
Aberrant activation of Wnt/β-catenin signaling in HCC has been attributed to activating 
mutations in CTNNB1 (20-25%) or loss of function mutations in AXIN1 (10%), AXIN2 
(3-4%) and APC (1%~2%) (4, 6, 7). 
The serine-threonine kinase receptor-associated protein (STRAP) encoded by the 
STRAP gene, harbors seven WD40-repeat domains (8). It is considered to be a 
scaffolding protein without enzymatic function that exerts regulatory functions on a 
variety of cellular processes ranging from signal transduction, transcriptional regulation, 
RNA processing, vesicular trafficking to cell cycle progression (9). STRAP was shown to 
be overexpressed and exert oncogenic properties in breast cancer, colorectal cancer 
(CRC) and lung carcinomas (10-12). Originally, STRAP was shown to inhibit canonical 
transforming growth factor-beta (TGF-β) signaling (13). Later, it became apparent that 
STRAP modulates various other cellular processes and signaling pathways such as 
signaling through ASK1, P53, PI3K/PDK1, and P21Cip1 (9, 14, 15). More recently, 
Wnt/β-catenin signaling was demonstrated to be stimulated by increased STRAP in CRC 
through binding with GSK-3β around the catalytic domain, which diminished 
subsequent ubiquitin-dependent degradation of β-catenin (16). However, the function of 
STRAP in HCC progression remains elusive. 
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In this study, we investigated the expression level of STRAP in HCC tumor tissues and 
used clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9-mediated 
gene editing to knockout STRAP in HCC cell lines. Our results suggest that upregulation 
of STRAP protein provides growth advantage to HCC cells via enhancing Wnt/β-catenin 
signaling. These observations identify STRAP as a new player in regulating 
Wnt/β-catenin signaling in HCC. 
 
Materials and methods 
Cell lines 
Human HCC cell lines Hep3B, HepG2, HepaRG, Huh6, Huh7, PLC/PRF/5, SNU398, 
SNU182 and SNU449 were cultured as reported previously (7). Identity of all cell lines 
was confirmed by STR genotyping. CTNNB1 and AXIN1 mutations reported in 
Supplemental Table S1, were confirmed in these HCC cell lines by Sanger sequencing 
and were in accordance with those reported at COSMIC, the Catalogue Of Somatic 
Mutations In Cancer (http://cancer.sanger.ac.uk) (17). For the preparation of Huh7 
conditioned medium, cells were cultured in complete DMEM medium for 3 days, 
followed by collection and filtration of medium according to standard procedures. 
Tissue microarray (TMA) 
TMA construction was described previously (18). Briefly, archived formalin fixed 
paraffin-embedded tissue samples from 141 patients who underwent hepatic resection 
for HCC at the Erasmus MC-University Medical Center Rotterdam, between 2004 and 
2013 were collected. Three or four 0.6mm cores from the tumor area as well as two 
0.6mm cores from the corresponding tumor free liver (TFL) area of these patients were 
taken. The TMAs were made using an automated tissue-arrayer ATA-27 (Beecher 
Instruments, Silver Spring MD, USA) or a manual tissue arrayer MTA-1 (Beecher 
Instruments). Clinicopathologic characteristics are presented in Supplemental Table S2. 
Database analysis 
The TCGA LIHC illuminahiseq_rnaseqv2_RSEM_genes_normalized (MD5) data were 
obtained from the Broad Institute’s Firehose GDAC website 
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(http://firebrowse.org/?cohort=LIHC&download_dialog=true). In this dataset 373 
hepatocellular carcinoma samples are available for which gene expression analysis was 
performed (19). In addition, 50 paired adjacent tumor-free tissues are also available for 
gene expression analysis. RNAseq levels of STRAP were obtained and matched to the 
available survival data. 
DEN induction of liver tumors in mice 
Mice of C57BL/6J background or mixed with C3H/HeOuJ or CD1 (all 3-4 weeks of age) 
were administrated weekly with Diethylnitrosamine (DEN) (intraperitoneal injection; 
100 mg/kg) for 6-17 weeks to induce liver tumor formation. Mice were sacrificed 3-16 
months after the last DEN injection, after which livers were fixed in PBS-buffered 
formalin and embedded in paraffin according to routine procedures. All animal 
experiments were approved by the Committee on the Ethics of Animal Experiments of 
the Erasmus Medical Center. 
Reagents 
The following antibodies were used for western blot analysis or 
immunohistochemistry staining. STRAP (611346, BD Transduction Laboratories™ and 
HPA027320, Atlas antibodies), β-catenin (610154, BD Transduction Laboratories™), 
Non-phospho (Active) β-catenin (Ser33/37/Thr41) (#8814, Cell Signaling Technology), 
Tubulin (sc-8035, Santa Cruz), β-actin (sc-47778, Santa Cruz) and anti-rabbit or 
anti-mouse IRDye-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, USA), 
HRP-conjugated anti-mouse polymer secondary antibody (EnvisionTM, DAKO, Glostrup, 
Denmark). Propidium iodide solution, diaminobenzidine (DAB) and crystal violet 
solution were purchased from Sigma (St. Louis, MO). 
Immunohistochemistry 
Paraffin embedded tumor slides were deparaffinized in xylene, rehydrated in graded 
alcohols and then rinsed in PBS with 0.025%Trition. Antigen retrieval was performed in 
a microwave in Tris/EDTA (pH 8) for 10 min. Endogenous peroxidase activity was 
blocked by incubation in 1.5% H2O2 at room temperature for 15 min. After blocking by 
5% nonfat dry milk in PBS, the sections were incubated with STRAP antibody (611346, 
BD Transduction Laboratories™) (1:100) at 4°C overnight. HRP-conjugated anti-mouse 
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polymer secondary antibody was then applied for 1 h. Then reaction products were 
visualized using DAB and counterstained with hematoxylin. STRAP staining was scored 
by two independent observers. The intensity of STRAP staining was classified in three 
categories: 0, 1, 2, respectively correlating with weak, moderate or strong staining, and 
scored by two independent investigators resulting in a Kappa test of 0.609 (for STRAP in 
HCC tumors), which was deemed acceptable. In our study, we generated STRAP 
knockout HCC cell lines that were used to test the specificity of the antibody 
(Supplemental Figure S1).  
β-catenin reporter assays 
The β-catenin reporter assays were basically performed as previously described (20, 
21). In short, twenty hours before transfection, we plated 0.5×105 cells per well on 
24-well plates. Each well was transfected with 250 ng Wnt Responsive Element (WRE) 
or Mutant Responsive Element (MRE) vectors and 10 ng CMV-Renilla using FuGENE®  
HD Transfection Reagent (E2311, Promega). We measured luciferase activities in a 
LumiStar Optima luminescence counter (BMG LabTech, Offenburg, Germany) and 
normalized the data for the transfection efficiency by using the Dual Luciferase Reporter 
Assay system (E1980, Promega) according to the manufacturer’s instruction. 
Transfections were performed twice in duplicate and the mean and standard error were 
calculated for each condition. The β-catenin reporter activities are shown as WRE/MRE 
ratios. 
Western blotting 
Cells were lysed in Laemmli sample buffer with 0.1 M DTT and heated for 10 minutes 
at 95°C, followed by loading and separation on a 10% sodium dodecyl 
sulphate-polyacrylamide gels (SDS-PAGE). After 90 min running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane 
(Invitrogen) for 1.5 h with an electric current of 250 mA. The membrane was blocked 
with Odyssey Blocking Buffer followed by incubation with primary antibody (1:1000) 
overnight at 4°C. Anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies 
(1:5000) were applied for 1 hour at room temperature. Blots were assayed for Tubulin 
or β-actin content as standardization of sample loading, scanned, and quantified by 
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Odyssey infrared imaging (Li-COR Biosciences, Lincoln, NE, USA). Results were 
visualized and quantified with Odyssey 3.0 software. 
Gene knockdown by small interfering RNA (siRNA) 
Smartpool ON-TARGETplus siRNAs targeting STRAP were purchased from 
Dharmacon. The ON-TARGETplus Non-targeting siRNA #2 was used as negative control. 
Cells were reverse-transfected in a 24-well plate using a total of 0.8 µl DharmaFECT 
formulation 4 (Thermo Fischer Scientific) and 25nM of each siRNA per well. Following 
72 h incubation, the effect of knockdown was tested by western blotting. Alternatively, 
48h after reverse transfection, the cells were transfected with WRE or MRE vectors and 
CMV-Renilla for β-catenin reporter assay. 
Construction of CRISPR/Cas9 STRAP-targeting vectors 
Single guide RNAs (sgRNAs) targeting exon 1 or 2 of human STRAP were designed 
using the following CRISPR design tool (http://crispr.mit.edu/). Supplemental table S3 
depicts the three selected sgRNAs, chosen because of lowest predicted potential exonic 
off-target sites. Oligos were dissolved at 100 pmol/µl and annealed by combining 10 µl 
of each with 2 µl of NEB buffer 3, heated in a PCR machine to 94°C for 4 minutes, 
removed and allowed to cool down to room temperature. Annealed oligos were diluted 
1000x in water of which 1 µl was combined with 100 ng of BbsI-digested and purified 
pX330 in a total ligation volume of 20 µl using 1.5 units T4 DNA ligase. Next, ligated 
plasmids were electroporated into DH10B E. coli. After plating, correct plasmids were 
identified and sequence-verified using standard procedures. 
Generation of STRAP knockout HCC cell lines 
Huh6 and Huh7 cell lines were transfected in 6-well plates using 7.5 µl FuGENE®  HD 
Transfection Reagent (E2311, Promega) and 2 µg of each pX330 plasmid per well 
together with 0.2 µg GFP expression construct. GFP expression was used to select the 
cells that received high levels of the pX330 CRISPR/Cas9 constructs. After incubation at 
37°C for 24 h, single cells were prepared for fluorescence activated cell sorting (FACS) to 
a 96-well plate. After single cell sorting, Huh7 cells were maintained in DMEM 
supplemented with either 20% FCS or 25% Huh7-conditioned medium. Huh6 was 
cultured in complete DMEM medium. 
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 Clones grown successfully from single cells were first subjected to western blotting 
with anti-STRAP antibody (611346, BD Transduction Laboratories). For each cell line, 
apparently successful STRAP knockout and control clones were selected for DNA 
sequence verification using oligos shown in Supplemental Table S4. For clones with 
complicated chromatograms, we also employed next-generation sequencing (NGS) on an 
Ion-Torrent device using the fusion method for amplicon library preparation. This 
method uses oligos designed to directly include barcodes and adaptors required for 
processing on the Ion-Torrent device (see Supplemental Table S5). PCR products were 
generated using Q5 proofreading polymerase (NEB) according to manufacturer’s 
instructions, followed by purification and NGS according to routine protocols. All 
selected clones were re-tested for STRAP-loss using an additional STRAP antibody 
(HPA027320, Atlas antibodies). Western blot result and observed sequence alterations 
are depicted in Supplemental Figure S2. 
Colony formation assays 
We performed two types of clonogenic assays, i.e. plating of single cells directly on cell 
culture surface or plating in soft-agar. For the former, 1000 cells for each clone were 
seeded in 6-well plates and were cultured in 2ml complete DMEM medium per well. Two 
weeks later, the cells were washed with PBS, fixed in 4% PBS-buffered 
paraformaldehyde for 10 min and stained with crystal violet solution. Number of 
colonies were counted under a microscope.  
For the soft-agar assay, a base layer of 0.3 ml of complete DMEM/F12 medium (2% 
B27, 1% N-2, 20 ng/ml FGF, 20 ng/ml EGF, 100 µg/ml Primocin) containing 0.6% 
soft-agar was allowed to settle in 24-well plates. Next, 0.6 ml of complete 0.6% soft-agar 
DMEM/F12 medium was added containing 1000 (Huh6) or 2000 (Huh7) single cells. 
After settling of the agar, 0.5 ml of liquid medium was added, which was replaced every 
other day. After 2 weeks of culturing, colonies were fixed and stained with 0.005% 
Crystal violet in 10% PBS-buffered Formalin. Pictures were taken of the complete 
24-well and colonies were automatically counted with ImageJ. All colony formation 
assays were performed in triplicates. The mean and standard error were calculated for 
each condition. 
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Periodic Acid Schiff (PAS) staining of cultured cells 
Cells were cultured in 6-well plates until they reached 60-70% confluency, Next, they 
were washed with PBS twice followed by fixation in 10% PBS-buffered formalin for 10 
min. After two ddH2O washes, cells were incubated with 0.5% Periodic Acid solution for 
10 min, followed by two ddH2O washes and incubation in Schiff’s reagent (Sigma Aldrich) 
for 15 min. Cells were washed in tap water and visualized under an inverted microscope.  
Quantitative real-time polymerase chain reaction (qRT-PCR) 
RNA was isolated with the Machery-NucleoSpin RNA II kit (BIOKE, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). CDNA 
was prepared from total RNA using a random-primed cDNA Synthesis Kit (TAKARA BIO 
INC) and subjected to quantitative Real-Time PCR analyses. Analyses were performed 
using the StepOne Real-Time PCR System and the StepOnev2.0 software (Applied 
Biosystem, Darmstadt, Germany). All expression levels are depicted relative to the 
expression of GAPDH. Primer sequences are provided in Supplemental Table S6. 
RNA extraction, Ilumina library preparation and sequencing 
Total RNA was isolated with the Machery-NucleoSpin RNA II kit (BIOKE, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). RNA 
quality was checked using a RNA Pico chip on the Agilent Bioanalyzer. Library was 
constructed and sequenced with an Illumina HiSeqTM2000 (GATC Biotech, Konstanz, 
Germany). Briefly, the mRNA was enriched using oligo-dT magnetic beads, followed by 
fragmentation (about 200 bp). Then the first strand of cDNA was synthesized using 
random hexamer-primer and the second strand was further synthesized in a reaction 
buffer including dNTPs, RNase H and DNA polymerase I. Double stranded cDNA was 
purified with magnetic beads. Then, the 3’-end single nucleotide A (adenine) was added 
and adapters were ligated to the fragments which were enriched by PCR amplification. 
RNA-sequencing analysis 
The Illumina single-end reads were trimmed to remove the TrueSeq adapter 
sequences using Trimmomatic (v.0.33). Subsequently, the reads were mapped to the 
human reference genome build hg38 with the RNA-seq aligner STAR (v2.4.2a) and the 
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Homo sapiens GENCODE v23 annotation. Raw counts were measured with 
summarizeOverlaps function from the Bioconductor GenomicAlignments package 
(v1.12.1) using the setting mode union. The differentially expressed genes were called 
with a generalized linear model using a negative binomial distribution and accounting 
for the different cell lines (Huh6 and Huh7). The calculations were performed by the 
DESeq2 package (v1.16.1). We applied a Wald-test to identify statistical significant 
differently expressed genes with a False Discover Rate (FDR) that was calculated using 
Benjamini Hochberg correction and set a threshold value of 0.01. After blind variance 
stabilizing log2 transformation of the counts, the differentially expressed genes were 
used to calculate scaled gene-wise values (Z-score). The scaled values were, clustered 
hierarchically with complete linkage using Euclidean distances and subsequently plotted 
in a heat map with pheatmap package(v1.0.8). Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) gene enrichment analyses were carried out 
as described previously (22). We used R(v 3.4.0) for statistics and visualization of the 
data. 
Statistical analysis 
All results were presented as mean ± SD or mean ± SEM as described in the figure 
legends. Comparison of STRAP protein staining between HCC tumor group and adjacent 
normal groups were performed with test of proportion. The t-test was used for 
statistical evaluation of number of colonies formed in the soft-agar colony assay. 
Differences were considered significant at a P value less than 0.05. 
Data accessibility 
The RNA-sequencing data from this study have been submitted to the Gene 
Expression Omnibus (GEO)(23) database under the accession number GSE101061. 
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Results 
STRAP protein is up-regulated in HCC tumor tissues 
In order to assess the expression level of STRAP protein in HCC lesions, we stained a 
tissue microarray (TMA) containing HCC tumors and patient matched adjacent normal 
tissues. For 109 tumor samples a STRAP intensity score could be obtained. In most 
normal samples STRAP protein was expressed at low to moderate levels, while it was 
significantly elevated in the majority of HCC tumors (Figure 1). Within the tumor cells, 
STRAP showed a predominant cytoplasmic location (Figure 1D). Similar results were 
observed in Diethylnitrosamine (DEN) induced liver tumors in mice, in which 22 out of 
28 tumor nodules showed increased STRAP expression relative to flanking normal liver 
tissue (Supplemental Figure S3). 
In our cohort, IHC-evaluated STRAP expression was not significantly associated with 
any of the available clinicopathologic characteristics presented in supplemental Table S2 
(data not shown), including tumor recurrence (HR 1.10; 95% CI 0.57-2.10, p=.785) or 
HCC specific mortality (HR 0.79; 95% CI 0.37-1.71, p=.557). Given that our 
semi-quantitative IHC analysis may miss subtle differences in expression levels, we 
explored an independent dataset, that is the TCGA liver cancer cohort, which includes 
373 HCC cases that were analyzed by RNA expression profiling (19). No significant 
difference in STRAP RNA expression was observed between tumors and 50 normal 
adjacent liver tissues. Survival analysis of the top and bottom 30% STRAP expressors 
revealed a significant trend (p=0.011) of reduced survival in the high expressing group, 
suggesting that higher STRAP levels may contribute to tumor progression 
(Supplemental Figure S4). 
Overall, these analyses show that STRAP protein levels are increased in most liver 
tumors of man and mouse, but that its expression level is only modestly associated with 
patient characteristics. 
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Figure 1. Elevated expression of STRAP in patient HCC tumor tissues. (A) The levels of STRAP protein 
positivity were scored from weak (0), moderate (1) to strong (2), both in the adjacent normal liver and 
HCC tumor tissue. (B) Distribution of normal liver and HCC tissues classified by above categories. 
Differences in the number of patients between normal liver and HCC tumors are highly significant 
(P<0.001, test of proportion). (C) Representative STRAP staining of a HCC tumor (T) with adjacent normal 
liver tissue (N); original magnification 100x. (D) STRAP shows a predominant cytoplasmic location in 
hepatocellular carcinoma cells; original magnification 630x. 
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Transcriptome analysis of STRAP knock-out clones by RNA sequencing 
We tested the baseline expression of STRAP in our panel of nine liver cancer cell lines. 
All showed readily detectable STRAP protein and RNA, with little variation between cell 
lines (Supplemental Figure S5). In order to determine the function of STRAP protein for 
supporting cell growth, we used the CRISPR/Cas9 technology to disrupt STRAP 
expression in Huh6 and Huh7 cell lines. As shown in Supplemental Figure S2, the STRAP 
protein was completely lost in the selected knockout clones of both cell lines.  
To investigate the genome-wide effects of STRAP in regulating gene expression in HCC 
cell lines, total RNA of selected STRAP knockout and control clones (n=3 each) was 
subjected to RNA sequencing. The hierarchical clustering results successfully 
distinguished the Huh6 from the Huh7 cell line. Importantly, the STRAP KO Huh6 clones 
preferentially clustered with Huh7 KO ones. Likewise, control Huh6 and Huh7 clones 
were clustered. According to STRAP genotype, 5605 differentially expressed genes 
(threshold FDR<0.01) were clustered in both Huh6 and Huh7 (Figure 2A). 
For validation of the differentially expressed genes identified from RNA sequencing, a 
total of eight genes were selected for qRT-PCR in Huh6 and Huh7 cell lines, which were 
among the top genes either up- or down-regulated. As shown in Figure 2B, log2 fold 
change of these genes tested by qRT-PCR significantly correlated with those from RNA 
sequencing (R=0.998 in Huh6 and R=0.913 in Huh7). Taken together, these data indicate 
that STRAP plays an important role, directly or indirectly, in the transcriptional 
regulation of many genes in HCC cell lines. 
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Figure 2. Differential expression profiles in STRAP knockout Huh6 and Huh7 clones. (A) Hierarchically 
clustered heat map using complete linkage showing scaled Z-score color key of normalized counts of 5605 
differentially expressed genes in 3 control (CON) and 3 STRAP knockout (KO) clones of Huh6 and Huh7. 
Columns represent clones and rows show the differentially expressed genes. (B) Comparison of relative 
log2 fold changes of selected genes tested by RNA-seq and qRT-PCR. The results are presented as log2 fold 
change ± Standard Error, n=3.. 
 
Loss of STRAP reduces expression of many metabolic and cell cycle related genes 
Both Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and 
Gene Ontology (GO) enrichment analysis revealed that many metabolic processes were 
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reduced in activity in the STRAP knockout clones. In addition, this analysis showed that 
cell cycle progression was significantly affected, as a result of STRAP loss in both Huh6 
as well as Huh7 (Figure 3A and B). Both the reduced expression of metabolic and cell 
cycle related genes are in line with the general slower growth of all knockout clones 
observed during routine culture (data not shown). To assess the role of STRAP on the 
reproductive viability of HCC cells, a colony formation assay on regular culture plates 
was employed with the STRAP knockout-clones and controls thereof. We observed that 
loss of STRAP dramatically decreased not only the number but also the size of Huh6 and 
Huh7 colonies (Figure 4). These results indicate that STRAP is important for an efficient 
outgrowth of single HCC cells. 
 
 
Figure 3. Loss of STRAP reduces expression of metabolic and cell cycle related genes. (A) KEGG Pathway 
Gene Set Enrichment and (B) Gene Ontology analysis of genes significantly higher expressed in the control 
clones. X-axis indicates P-value in the –log10 scale. 
Chapter 5 
130 
 
 
Figure 4. Loss of STRAP perturbs the capacity of colony formation in HCC cell lines. (A,B) Deletion of 
STRAP dramatically inhibits the colony formation of Huh6 and Huh7 cell lines. The number of colonies in 
each well was counted (mean ± SD, n=4 for each clone) 
Loss of STRAP attenuates Wnt/β-catenin signaling activity 
It has been reported that upregulation of STRAP correlates with increased 
Wnt/β-catenin signaling activity in colorectal cancer (16). We wondered whether this 
also holds true for HCC cells, most of which are known to also depend on β-catenin 
signaling for sustaining optimal growth (24). To this aim, we evaluated the expression 
change within the RNA-seq data of several (liver specific) β-catenin signaling target 
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genes reported previously, i.e. AXIN2, LGR5, MYC, CCND1, GLUL, RGN and BIRC5 (also 
known as Survivin) (25). In Huh7 all these genes were downregulated in the STRAP 
knockout clones with the exception of RGN and GLUL. In the CTNNB1 mutant Huh6 cells 
the differences were less obvious but most genes showed a trend towards lower 
expression (Figure 5A). The effect of STRAP on Wnt/β-catenin signaling activity was 
confirmed using a more sensitive β-catenin reporter assay (Figure 5B). 
Using siRNA mediated knockdown of STRAP, similar reductions in β-catenin reporter 
activity were observed in the parental Huh6 and Huh7 lines as well as in four additional 
HCC lines, indicating that STRAP is required to maintain optimal β-catenin signaling in 
most, if not all, HCC lines (Figure 5C). This even is the case in the cell lines endogenously 
expressing a dominant acting β-catenin variant (Huh6, SNU398 and HepG2). 
STRAP has been shown to bind to GSK3β around the catalytic domain, thereby 
reducing the N-terminal phosphorylation of β-catenin (16, 26) and subsequently 
increasing the active signaling pool of β-catenin, i.e. unphosphorylated at S33/ S37/T41. 
Hence, we investigated the amount of the active β-catenin signaling pool present in the 
HCC clones. As shown in Figure 5D, Huh6 showed reduced levels of active β-catenin in 
the STRAP knockout clones, whereas no change was observed in Huh7. 
Besides N-terminal phosphorylation, the signaling strength of β-catenin is also 
regulated by phosphorylation at its C-terminus. For example, S675 phosphorylation by 
protein kinase A (PKA) has been shown to increase Wnt signaling by recruiting 
transcriptional co-activators (21, 27-29). To investigate whether STRAP promotes 
Wnt/β-catenin signaling through indirectly affecting the phosphorylation of S675, we 
tested its levels. As indicated in Figure 5E, reduced levels of phosphorylated β-catenin at 
S675 were observed in the STRAP knockout clones of Huh6 while no clear change was 
seen in the Huh7 cell line. Thus, in Huh6 loss of STRAP is accompanied by lower levels of 
unphosphorylated N-terminal β-catenin and reduced phosphorylation at its C-terminus, 
both features that are associated with reduced signaling, whereas no alteration is 
observed in Huh7. 
Together, these findings suggest that STRAP enhances Wnt/β-catenin signaling in all 
tested HCC cells. The exact molecular mechanism appears however to differ between cell 
lines.  
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Figure 5. Loss of STRAP reduces Wnt/β-catenin signaling activity in HCC cell lines. (A) Log2 fold change of 
(liver specific) target genes of Wnt/β-catenin signaling in STRAP knockout clones derived from the 
RNA-seq data. (B) β-catenin luciferase reporter assay showing reduced β-catenin signaling activity in 
STRAP knockout clones of Huh6 and Huh7 cell lines compared to controls (mean ± SD, n=2, two times). 
The β-catenin reporter activities are depicted as WRE/MRE ratios. (C) SiRNA mediated knockdown of 
STRAP suppresses β-catenin signaling activity in HCC cell lines (mean ± SD, n=2, two times). Values are 
depicted relative to the WRE/MRE ratios obtained for the controls, which are arbitrarily set to 1. (D) 
Deletion of STRAP decreases the abundance of active β-catenin (unphospho-Ser33/Ser37/Thr41) in Huh6 
cells. (E) The level of phosphorylated β-catenin at S675 is diminished in STRAP knockout Huh6 cell clones. 
Values for active and pS675 β-catenin are depicted relative to signal intensities obtained for total 
β-catenin. Cells were grown and blotted 3 independent times. Mean ± SD is shown; values were analyzed 
using GraphPad column t-test; * p<0.05. 
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Loss of STRAP associates with reduced stemness and increased differentiation 
markers 
Wnt/β-catenin signaling is essential for the homeostatic self-renewal and 
proliferation of the hepatic stem/progenitor cells (30). In particular, Wnt/β-catenin 
driven AXIN2+ (31) and LGR5+ (32) cells have been identified as stem cells that 
self-renew and give rise to mature hepatocytes. STRAP itself has also been linked to 
stemness in colorectal cancer (33). Therefore, loss of STRAP and the resulting reduction 
in β-catenin signaling may lead to reduced expression of stem/progenitor cell markers. 
We observed a clear reduction at the transcription level of AXIN2 and LGR5 and other 
liver progenitor markers (SOX9, CD44 and PROM1/CD133) (34) in STRAP knockout 
Huh6 cells. In Huh7, expression of AXIN2, LGR5 and PROM1 but not SOX9 and CD44 
were decreased (supplemental Figure S6A).   
The colony formation assay shown in Figure 4 partially supports the stem cell 
assumption, but may be biased by differences in plating efficiency associated with 
STRAP-loss. Therefore, we performed a similar assay by plating the cells in soft agar. As 
shown in Figure 6 a significant reduction in colonies is formed in the STRAP knockout 
clones of Huh6 (p=0.001), while no clear difference is seen for Huh7.  
Conversely, STRAP loss increased most liver differentiation related genes, such as ALB, 
AFP and HNF4A (35, 36) in Huh6 and more obviously in Huh7 cells (Supplemental 
Figure S6B). To corroborate this observation, we explored glycogen storage as a marker 
of differentiation in liver cancer cells using PAS staining (Figure 7). All knockout clones 
of Huh6 showed multiple cells with a prominent PAS staining, while this was rarely 
visible in the control clones. In Huh7 the difference was less obvious, although also here 
a trend towards more positivity was observed in the knock-out clones. 
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Figure 6. Soft-agar colony formation assay. STRAP knockout significantly (P¼ 0.001) reduces the number 
of colonies formed from single Huh6 cells. No significant difference is observed for Huh7 
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Figure 7. Glycogen storage is increased in STRAP knockout clones. PAS staining ofclones grown to 60% to 
70% confluency shows increased glycogen storage in all Huh6 knockout clones, whereas a trend in the 
same direction is visible for Huh7. 
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Discussion 
STRAP has been identified as a scaffolding protein that is upregulated in breast, lung 
and colorectal cancers, and was shown to promote their growth (10-12). Here we show 
that also in most hepatocellular cancers increased levels of STRAP protein can be 
observed. Furthermore, knockout experiments in two different HCC cell lines showed 
that its expression is required to support optimal growth. Mechanistically we provide 
evidence that many signaling pathways and metabolic processes are affected following 
STRAP loss, including the Wnt/β-catenin signaling pathway. 
 Given the well-known importance of β-catenin signaling to sustain HCC growth, we 
have investigated this pathway in more detail (24, 25). Knockout/down of STRAP 
resulted in reduced β-catenin signaling in all six HCC lines investigated, regardless of the 
underlying CTNNB1 or AXIN1 mutation being present in these lines. This is largely in 
line with the observation of Yuan et al for colorectal cancer cells (16). Mechanistically, 
STRAP has been shown to bind to the catalytic site of GSK3β, effectively resulting in 
reduced N-terminal phosphorylation and reduced breakdown of β-catenin (16, 26). 
Hence, loss of STRAP is expected to result in more GSK3-mediated phosphorylation of 
β-catenin, which is in accordance with the notable decrease in non-phosphorylated 
(active) β-catenin observed in Huh6. In Huh6 a second mechanism appears active by 
which STRAP increases overall β-catenin signaling. PKA-mediated phosphorylation of 
β-catenin at S675, previously shown to result in increased signaling (21, 27-29), is about 
2-fold higher in the clones that have retained STRAP expression. This result suggests 
that STRAP may be involved in modulating PKA activity through yet unknown 
mechanisms. Nevertheless, Huh7 cells apparently share neither mechanism for STRAP 
to support Wnt/β-catenin signaling, despite being one of the more sensitive cell lines 
(see Figures 5B and 5C), suggesting alternative routes involved. As Wnt/β-catenin 
signaling can be fine-tuned at multiple levels (37), uncovering the exact mechanism 
specifically for Huh7 is outside the scope of this current manuscript. Whichever the 
exact mechanism, our results show that the increased STRAP expression observed in 
most HCCs will support their growth by increasing overall β-catenin signaling. 
 The Wnt/β-catenin signaling pathway is well-known for its role in (cancer) stem cell 
maintenance (30-32, 38, 39). Accordingly, the reduced β-catenin signaling following 
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knockout of STRAP, is associated with lower expression of the β-catenin regulated stem 
cell markers AXIN2 and LGR5. In addition, several other liver progenitor markers (SOX9, 
CD44 and PROM1/CD133) are reduced in expression, whereas differentiation markers 
are elevated. These results suggest that one mechanism by which elevated STRAP 
expression supports HCC growth is to shift the balance towards the induction of stem 
cell features. This observation is in line with the work of Jin et al. who showed that 
STRAP promotes stem cell features in several colorectal cancer cell lines (33). 
Besides its role in fine-tuning β-catenin signaling, STRAP has also been linked to 
various other cellular processes likely contributing to HCC cell viability (9, 14). One of 
the first functions attributed to STRAP was its role in inhibiting TGF-β signaling (13). In 
the normal liver this signaling pathway has a crucial role in limiting hepatocyte 
proliferation and inducing differentiation (40). Likewise, TGF-β signaling is considered 
to act as a tumor suppressor during the early stages of liver tumor formation by 
inducing cell-cycle arrest and apoptosis. As such, the elevated STRAP levels that we 
observe in HCC may contribute to tumor growth by restraining the tumor-suppressive 
effects of TGF-β, which is supported by the re-activation of several TGF-β 
anti-proliferative (CDKN1A, CDKN2B, CDKN1C and EIF4EBP1) and pro-apoptotic (BIK, 
BCL2L11, DAPK1, FAS and GADD45B) target genes (41, 42) derived from RNA-seq data 
following STRAP loss in Huh6 and Huh7 cells (Supplemental Figure S6C). However, the 
role of TGF-β signaling in liver cancer is complicated by the observation that a subset of 
tumors become resistant to the cytostatic and apoptotic effects of TGF-β, and in fact 
exploit TGF-β to support their growth, migration and invasion during later stages (40, 
43). This indicates that the specific contribution of STRAP to TGF-β-mediated tumor 
suppression has to be evaluated on a case-by-case basis. 
In summary, we show that most HCCs show upregulation of STRAP expression. Our in 
vitro analyses suggest that its elevated expression is important to support optimal 
growth by affecting a variety of metabolic processes and signaling pathways of known 
importance for liver cancer. Especially, its contribution to increase Wnt/β-catenin 
signaling is likely to be a major effector of its tumor-promoting role. 
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Supplementary Figures and Tables 
 
Figure S1. Specificity of STRAP antibody tested on a STRAP knock-out Huh6 clone and control thereof. For 
this purpose, both cell lines were formalin-fixed and embedded in paraffin. 
 
Figure S2. Knockout of the STRAP gene by CRISPR/Cas9 technology in HCC cell lines.Huh6 and Huh7 were 
transfected with STRAP-targeting vectors and single-cell sorted by FACS. The surviving clones were 
subjected to western blot. Depicted are STRAP protein levels of independent control and knock-out clones 
selected for further analysis. The lower panel shows the sequence alterations of each STRAP knock-out 
clone. All control clones showed only the wild-type sequence. The insertion of 81 nucleotides in Huh6 
KO#33 results in additional 27 amino acids within the WD40 region, which apparently makes the protein 
highly unstable as demonstrated by no detectable protein using two antibodies 
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Figure S3. Elevated expression of STRAP in DEN-induced mouse liver tumors (T) compared with flanking 
normal liver tissue (N). 
Figure S4. Analysis of the TCGA liver cancer cohort reveals that no significant difference in average STRAP 
RNA levels is observed between normal and tumor samples. Kaplan-Meier survival analysis and a log-rank 
test of the top and bottom 30% STRAP expressors revealed a significant trend (p=0.011) of reduced 
survival in the high expressing group. 
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Figure S5. Baseline levels of STRAP protein and RNA in a panel of 9 HCC cell lines. 
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Figure S6. Log2 fold change of liver stemness markers (A), liver differentiation related genes (B) and 
TGF-β signaling target genes (C) in STRAP knock-out clones compared to controls. The results are 
presented as log2 fold change ± Standard Error, n=3. 
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Supplemental Table S1. Selected STRAP sgRNAs 
Species Gene target  gRNA Sequence 
Human STRAP exon2 sgRNA1 TTGGGGTGCAACACTGAATA 
 STRAP exon1 sgRNA2 AATCAACCACGGGTCGCGTG 
 STRAP exon1 sgRNA3 CACGCGACCCGTGGTTGATT 
 
 
Supplemental Table S2. Primer sequences of STRAP used for Sanger sequencing 
Exons Forward Sequence (5’~3’)  Reverse Sequence (5’~3’) 
Exon1  CCCTTCTTTTCCTGTTGCC GTGTTGGCTCTCATCTCAG 
Exon2  GGTGGTAGTTAAATAGCTG TGGGATCAAACATGCGTTC 
 
 
Supplemental Table S3. Primer sequence used for Ion Torrent sequencing 
Gene Forward Sequence (5’~3’)  Reverse Sequence (5’~3’) 
STRAP 
Adapter 
A-Barcode-CCCTTCTTTTCCTGTTGCC 
Adapter 
PI-Barcode-GTGTTGGCTCTCATCTCAG 
 
 
Supplemental Table S4. Primer sequences used for qRT-PCR 
Gene Forward Sequence (5’~3’)  Reverse Sequence (5’~3’) 
DCDC2 ACTTGGACATAGGAGAAATCAAGA CGAGCTGACACGTTGATCCT 
NTHL1 TATGAGGGCTCGGACAGTGA TTTGGTTTGGCTGGAGAGCA 
RPS26 AAACATAGTGGAGGCCGCAG CACATACAGCTTGGGAAGCAC 
OLR1 CCTTGCTCGGAAGCTGAATG TCTCCATGCCAGATCCAGTC 
ABHD13 CCGGCGACACCCGAG ACAAAGTTCCACAGCATCCAG 
KLHL42 GGCCTCCATGAACCAGAAGA GTTCCGGTCTCTGGTAGTGTAT 
ZNF853 AGCAGGAAATGCTCCACCAG GTGGACTGCTGTTCCTCTCC 
LGR5 ACACGTACCCACAGAAGCTC CTAAAAGCCTGGACGGGGAT 
 
Supplemental Table S5. Symmetric Measures 
 Value Asymp.Std. Errora Approx. Tb Approx. Sig. 
Measure of Agreement    
Kappa 
,609 ,064 8,453 ,000 
N of Valid Cases 115    
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 
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Supplemental Table S6 Genes information 
Gene Protein 
STRAP STRAP 
A scaffolding protein without enzymatic function exerting regulatory 
functions on a variety of cellular processes 
CTNNB1 β-catenin 
A dual function protein involved in regulation and coordination of 
cell–cell adhesion and gene transcription 
AXIN1 AXIN1 
To form a destruction complex with APC, GSK3 and CK1ɑ leading to 
the degradation of β-catenin 
AXIN2 AXIN2 
To form a destruction complex with APC, GSK3 and CK1ɑ leading to 
the degradation of β-catenin 
APC APC 
A tumor suppressor, negatively regulating β-catenin by forming a 
destruction complex with AXIN1/2, GSK3 and CK1ɑ 
GSK3 GSK3 A Ser/Thr kinase 
CSNK1A1 CK1a Kinase with preferential acidic protein targets 
LGR5 LGR5 
The receptor of R-spondin family of stem cell factors to potentiate 
Wnt/β-catenin signaling 
ASK1 MAP3K5 Mitogen-activated protein kinase 
PI3K PIK3CA Phosphatidylinositol 3-kinase 
PDK1 PDK1 Pyruvate dehydrogenase kinase 
DCDC2 DCDC2 
A protein with two doublecortin peptide domains binding to tubulin 
and enhancing microtubule polymerization 
NTHL1 NTHL1 
A bifunctional DNA glycosylase that has an associated 
beta-elimination activity 
RPS26 
40S ribosomal protein 
S26 
A ribosomal protein as a component of the 40S subunit 
OLR1 OLR1 
The protein binds, internalizes and degrades oxidized low-density 
lipoprotein 
ABHD13 ABHD13 Unknown 
KLHL42 KLHL42 Unknown 
ZNF853 
Zinc finger protein 
853 
A protein contains the zinc finger, a structural motif, for the 
coordination of one or more zinc ions in order to stabilize the fold. 
MYC MYC 
A multifunctional, nuclear phosphoprotein that plays a role in cell 
cycle progression, apoptosis and cellular transformation 
CCND1 Cyclin D1 
A member of highly conserved cyclin family, whose members are 
characterized by a dramatic periodicity in protein abundance 
throughout the cell cycle 
GLUL 
glutamate-ammonia 
ligase 
It catalyzes the synthesis of glutamine from glutamate and ammonia 
in an ATP-dependent reaction 
RGN Regucalcin It may have an important role in calcium homeostasis 
BIRC5 
BIRC5/ 
Survivin 
This protein functions to inhibit caspase activation, thereby leading to 
negative regulation of apoptosis or programmed cell death 
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SOX9 SOX-9 A transcription factor 
CD44 CD44 
CD44 participates in a wide variety of cellular functions including 
lymphocyte activation, recirculation and homing, hematopoiesis, and 
tumor metastasis. 
PROM1 Prominin-1/CD133 
The precise function of CD133 remains unknown, it has been 
proposed to act as an organizer of cell membrane topology 
ALB Albumin Its main function is to regulate the Oncotic pressure of blood 
AFP alpha fetoprotein 
Alpha-fetoprotein expression in adults is often associated with 
hepatoma or teratoma 
HNF4A HNF4A/ NR2A1 HNF4A is a nuclear transcription factor 
HNF1A HNF1A A transcription factor expressed in organs of endoderm origin 
HNF1B HNF1B  HNF1B is a nuclear transcription factor 
FOXA1 FOXA1/ HNF-3A 
A transcriptional activator for liver-specific transcripts such as 
albumin and transthyretin 
FOXA2 
FOXA2/ HNF-3B/ 
TCF-3B 
A transcriptional activator for liver-specific transcripts such as 
albumin and transthyretin 
FOXA3 
FOXA3/ HNF-3G/ 
TCF-3G 
A transcriptional activator for liver-specific transcripts such as 
albumin and transthyretin 
PPARA PPARɑ/NR1C1 
A transcription factor and a major regulator of lipid metabolism in the 
liver 
GATA6 GATA6 
This protein preferentially binds (A/T/C)GAT(A/T)(A) of the 
consensus binding sequence. 
GATA4 GATA4 A member of the GATA family of zinc finger transcription factors 
HHEX HHEX 
A member of the homeobox family of transcription factors, many of 
which are involved in the development of liver, thyroid, forebrain etc. 
TBX3 TBX3 
A member of T-box family which are the transcription factors involved 
in the regulation of developmental processes 
APOB Apolipoprotein B 
Apolipoprotein B is the primary apolipoprotein of chylomicrons, 
VLDL, IDL, and LDL particles 
APOA1 Apolipoprotein A1 
Apolipoprotein A1 is the major protein component of high density 
lipoprotein particles in plasma. 
APOA2 Apolipoprotein A2 
The second most abundant protein of the high density lipoprotein 
particles 
APOA4 Apolipoprotein A4 
Apolipoprotein A4 is secreted into circulation on the surface of newly 
synthesized chylomicron particles 
APOC2 Apolipoprotein C2 A component of very low density lipoproteins and chylomicrons 
APOC3 Apolipoprotein C3 A component of very low density lipoprotein 
TF Transferrin 
Transferrins are iron-binding blood plasma glycoproteins that control 
the level of free iron (Fe) in biological fluids 
MTTP MTTP This protein plays a central role in lipoprotein assembly 
SHBG SHBG/SSBG 
A glycoprotein that binds to the two sex hormones: androgen and 
estrogen 
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CYP2C9 CYP2C9 
An important cytochrome P450 enzyme with a major role in the 
oxidation of both xenobiotic and endogenous compounds 
CYP2D6 CYP2D6 
A member of the cytochrome P450 mixed-function oxidase system, 
is one of the most important enzymes involved in the metabolism of 
xenobiotics in the body 
EPO 
Erythropoietin/ 
hematopoietin 
A hormone that induces red blood cell production 
AGT Angiotensinogen 
Angiotensin is a peptide hormone that causes vasoconstriction and a 
subsequent increase in blood pressure 
AMBP AMBP AMBP interacts with CD79A 
CDKN1A p21Cip1 
A cyclin-dependent kinase inhibitor (CKI) that is capable of inhibiting 
all cyclin/CDK complexes 
CDKN2B CDKN2B A cyclin-dependent kinase inhibitor 
CDKN1C CDKN1C 
A tight-binding inhibitor of several G1 cyclin/Cdk complexes and a 
negative regulator of cell proliferation 
EIF4EBP1 4E-BP1 
Interaction of this protein with eIF4E inhibits complex assembly and 
represses translation 
BIK 
Bcl-2-interacting 
killer 
Interaction of this protein with cellular and viral survival-promoting 
proteins, such as BCL2 and the Epstein-Barr virus enhances 
programmed cell death 
BCL2L11 BCL2L11 
Interaction of this protein with other members of the BCL-2 protein 
family, including BCL2, BCL2L1/BCL-X(L), and MCL1, activates 
apoptosis 
DAPK1 DAPK1 
A positive mediator of gamma-interferon induced programmed cell 
death 
FAS 
Fas cell surface 
death receptor 
The Fas receptor is a death receptor on the surface of cells that 
leads to programmed cell death (apoptosis) 
GADD45B GADD45B 
GADD45B responds to environmental stresses by mediating 
activation of the p38/JNK pathway and is involved in the regulation 
of growth and apoptosis 
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Abstract 
CCAAT/Enhancer Binding Protein Delta (CEBPD) is associated with the regulation of 
apoptosis and cell proliferation and is a candidate tumor suppressor gene. Here we 
investigated its role in hepatocellular carcinoma (HCC). We observe that CEBPD mRNA 
expression is significantly down-regulated in HCC tumors as compared to adjacent 
tissues. Protein levels of CEBPD are also lower in tumors relative to adjacent tissues. 
Reduced expression of CEBPD in the tumor correlates with worse clinical outcome. In 
both Huh7 and HepG2 cells, shRNA-mediated CEBPD knockdown significantly reduces 
cell proliferation, single cell colony formation and arrests cells in the G0/G1 phase. 
Subcutaneous xenografting of Huh7 in nude mice show that CEBPD knockdown results 
in smaller tumors. Gene expression analysis shows that CEBPD modulates interleukin-1 
(IL-1) signaling. We conclude that CEBPD expression uncouples cancer compartment 
expansion and clinical outcome in HCC, potentially by modulating interleukin-1 
signaling. Thus although our results support the notion that CEBPD acts as a tumor 
suppressor in HCC, its action does not involve impairing compartment expansion per se 
but more likely acts through improving anti-cancer immunity. 
 
Short summary 
We demonstrate that candidate tumor suppressor gene CCAAT/Enhancer Binding 
Protein Delta (CEBPD) downregulation provokes poor prognosis of clinical 
hepatocellular carcinoma (HCC). Remarkably, CEBPD drives HCC compartment 
expansion in experimental HCC. Interaction of CEBP with interleukin signaling may 
explain this discrepancy. 
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Introduction 
Cancerous disease is characterized by abnormal cell growth with the potential to 
invade or spread to other parts of the body [1]. As it ultimately involves the withdrawal 
of physiological anti-expansionary control from the cancer cells, suppression of 
expansion of the cancer cell compartment size is the mainstay of current pre-clinical 
research. To this end, novel anti-cancer strategies are explored by measuring cell 
proliferation and death in cell cultures and by visualizing tumor expansion in 
experimental rodents, most-often in xenograft models. Although this approach has been 
proven successful in forming the conceptual basis for novel therapy in many forms of 
cancers, it is fair to say that this approach has proven disappointing for a range of 
therapy-resistant oncological manifestations, suggesting that these cancer models only 
partially capture disease dynamics in humans [2]. Nevertheless, the notion that cancer 
compartment expansion constitutes the most relevant parameter in therapy-directed 
oncological research remains largely unchallenged. This is especially the case for those 
tumor types that are refractory to current therapies and thus are clinically only subject 
to palliative therapy [3].  
An important cancer type in this regard is hepatocellular carcinoma (HCC). HCC is the 
second cause of cancer-related death world-wide [4,5]. The disease is unusually 
resistant to therapies other as surgery, and thus is associated with very high fatality [6], 
especially in metastatic disease. The latter is depressingly common as early symptoms 
are inconspicuous and disease only becomes manifest at advanced stages. With more 
than 0.5 million new cases arising every year, the quest for devising a novel therapy for 
the treatment of HCC is one of utmost urgency [7]. Numerous studies have been directed 
at understanding the molecular processes driving HCC cell proliferation and to develop 
strategies aimed at inhibiting this proliferation. These studies, however, have yet largely 
failed to establish strategies that counteract clinical HCC, raising questions as to the 
extent to which the experimental models used reflect human disease faithfully. 
An important consideration to take into account in this respect is the influence and to 
a certain extent also the species-specific actions of the tumor stroma [8]. Although HCC 
xenografts in mice are supported by murine-derived stromal structures, we observed 
earlier that co-grafting human HCC with human mesenchymal cells substantially 
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promotes HCC progression [9]. It is thus possible that the incomplete HCC-stromal 
interaction in preclinical models, as a consequence of defective species compatibility, 
results in the loss of important aspects of the regulation of the HCC tumor expansion 
process. In vitro modeling often does not involve stromal-cancer cell interactions at all. 
Thus if it could be shown that biological effects in HCC have alternative consequences in 
often-used preclinical models of disease and in clinical practice. 
This consideration prompted us to explore both the clinical and preclinical 
importance of CCAAT/Enhancer Binding Protein Delta (CEBPD), which appears involved 
in oncological processes in general through modulating stroma-cancer cell interaction. 
CEBPD is recognized as an inflammatory response factor and plays a critical role in 
activating the innate immune response [10]. CEBPD is a bZIP transcription factor that 
belongs to the CEBPD family, which members exert their action through forming homo- 
and hetero-dimers and subsequent binding to specific DNA regulatory sequences, 
especially in the control of target gene expression [11,12] and regulation of proliferation 
[13], cell cycle, apoptosis, metastasis and inflammation cytokine signalling [14] 
following appropriate extracellular cues. On one hand, CEBPD expression is closely 
linked to the cancer tumorigenesis, whereas, on the other hand, its action appears highly 
context dependent. CEBPD seems, therefore, a candidate gene for testing whether 
preclinical compartment expansion and clinical effects can be uncoupled in relation to 
HCC.  
Our results demonstrate that CEBPD has a dualistic role in HCC. Its expression 
appears protective in HCC patients, but in preclinical models, it supports the HCC 
process. Our results thus show that CEBPD uncouples preclinical models of HCC with 
clinical disease. The apparent lack of correlation suggests that current preclinical 
models do not fully capture HCC and this may explain the failure of such models to 
identify novel treatment approaches. 
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Materials and methods 
Cell culture 
Monthly short tandem repeat identity-verified (verification commercially performed 
by the molecular pathology department of the Erasmus MC) and American Type Culture 
Collection (ATCC, Manassas, VA)-obtained mycoplasma-free (monthly commercially 
checked by GATC Biotech, Konstanz, Germany) human HCC cell lines were maintained as 
described previously [15]. In brief, HEK29, Hep3B, Huh6, Huh7, PLC/ PRF/5, SNU182, 
SNU398 and SNU449 were cultured in DMEM medium (Lonza, Breda, The Netherlands) 
supplemented with 10% fetal bovine serum (Sigma–Aldrich) and 1% 
penicillin/streptomycin (Gibco, Bleiswijk, The Netherlands). HepG2 cells were cultured 
on fibronectin/collagen/albumin-coated plates (AthenaES) in Williams E medium 
(Invitrogen-Gibco, Breda, the Netherlands) complemented with 10% (v/v) fetal calf 
serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine. The 
human liver organoids were cultured as described previously [16]. Cell lines were 
routinely confirmed to be mycoplasma free using the LookOut Mycoplasma PCR 
Detection Kit (Sigma-Aldrich). Cell counting process was performed by using Countess™ 
II Automated Cell Counter (Termo Fisher Scientifc). 
Tissue Microarray and TCGA dataset 
Archived formalin fixed paraffin-embedded tissue samples from 154 patients who 
underwent hepatic resection for HCC at Erasmus MC-University Medical Center (EMC, n 
= 94) or Amsterdam Medical Center (AMC, n = 60) between June 2001 and July 2014, 
were used for this study. Clinical data of this HCC cohort have been published previously 
[17]. For TMA slides, three or four 0.6 mm cores had been obtained from the tumorous 
area of 141 HCC patients and two 0.6 mm cores had been obtained from the paired 
tumor-free liver (TFL) area of 133 of these patients. Vital tumor areas and tumor-free 
liver tissue were identified by experienced gastrointestinal pathologists using 
earlier-archived hematoxylin-stained slides. The TMAs were constructed employing an 
automated tissue-arrayer (ATA-27). The use of patient materials was approved by the 
medical ethical committee of Erasmus MC (Medisch Ethische Toetsings Commissie 
Erasmus MC). Immunohistochemical scoring was conducted by two independent 
investigators (PL and KC) blinded to clinical outcome and differences resolved by 
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mutual agreement. In tumor tissues stained nuclei of tumor cells were scored, and in 
TFL stained hepatocyte nuclei. Percentages of stained nuclei were scored as 1 (<25%), 2 
(25%- 70%), or 3 (>70%). In addition, the intensity of staining was defined from zero to 
three.  Expression level was calculated by multiplication of intensity score and 
percentage score, resulting in levels ranging from 0 – 9.  
TCGA LIHC RNA-Seq (level 3) and corresponding clinical data were downloaded from 
(https://tcgadata.nci.nih.gov/tcga/). There are 371 patient’s tumor samples and 
corresponding 50 paired adjacent tumor-free tissues in this publically available dataset.   
Lentiviral-shRNA packaging and infection 
Hek293 cells were transfected with packaging plasmids and pLKO.1 based shRNA 
lentiviral vectors (Biomics Center in Erasmus Medical Center) targeting CEBPD, a 
scrambled control vector (shCTR) was also used. After 3 days infection, HepG2 and 
Huh7 cells were subjected to selection by puromycin (3 μg/mL); shRNA sequences are 
listed in the Supplementary Table S1. The knockdown efficiency is further confirmed by 
qRT-PCR (Supplementary Figure1) and Western Blot. 
Western blot analysis 
Western blot analysis has been extensively described elsewhere [18]. In short, protein 
samples were collected in a Laemmli sample buffer with 0.1 M DTT, and subsequently 
heated for 5 minutes at 95°C. Protein lysates were then subjected to polyacrylamide gel 
electrophoresis on a 8%-15% SDS gel for protein size-based separation by 
electrophoresis. All the Primary antibodies against CEBPD (sc-636), β-actin (sc-47778) 
(at a final dilution of 1:1000, Supplementary Table S2 ) were incubated with the 
membranes at 4°C for an overnight period. Next, 1 hour with an IRDye-conjugated 
secondary antibody (1:5000 anti-rabbit or 1:10000 anti-mouse dilution) at room 
temperature. Protein intensity was detected with the Odyssey 3.0 Infrared Imaging 
System. 
Quantitative Real-time PCR(qRT-PCR) 
A Machery-NucleoSpin RNA II kit (Bioke, Leiden, the Netherlands) was used for RNA 
isolation. The reverse transcription to produce cDNA was performed using a Takara 
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cDNA Synthesis Kit with random primers (Takara Bio, Inc., Shiga, Japan). Quantification 
of gene expression in HCC cell lines was quantified using SYBR-Green-based (Applied 
Biosystems®  SYBR®  Green PCR Master Mix ) real-time PCR on the StepOnePlus™ 
System (Thermo Fisher Scientific Life Sciences). GAPDH was used as a housekeeping 
gene and expression level of target genes was normalized to GAPDH by the 2-ΔΔCT 
method. Primers sequences involved in this study were listed in Supplementary Table 
S3.  
Cell proliferation and Colony formation assay 
Cell proliferation was measured essentially similar as described earlier [19]. In short, 
CEBPD stable knockdown cells and scrambled sequence control cells were seeded in a 
96-well microtiter plate with 6 replicate wells. Measurements were taken from day 1 to
7, with an interval of two days. For measurements 10 mM 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to each well. After 3 hours of incubation at 37°C under a 5% CO2 atmosphere, the 
medium was completely removed and replaced by 100 μl DMSO which dissolves 
reaction products that indicate cell viability. The absorbance of each well will be 
measured at absorbance 490 nm by a microplate absorbance reader (BIO-RAD). 
For colony formation, cells were harvested and resuspended in culture medium. A 
total of 1000 cells were seeded in 6-well tissue culture plates, with 3 independent wells 
for each experimental condition. After 14 days, the medium was thoroughly removed 
followed by two times of washing with PBS and the addition of a 0.5% crystal violet 
solution was then used for 15 min to stain cells. The number of colonies that 
contained >20 cells was analyzed and counted by Image J. 
Cell cycle analysis by propidium iodide 
5 x 105 cells were seeded in 6-well plates and harvested when a confluence of about 
80% was reached. Cells were washed two times with PBS and fixed in ice-cold 70% 
ethanol. Cells were pelleted by centrifugation at 2000 rpm for 5mins, followed by 2 
washes in PBS. The resulting pellets were subsequently stained employing 50 mg/ml 
propidium iodide and 0.1 mg/ml RNase for 30mins at room temperature and then 
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subjected to flow cytometric analysis. Cell cycle status was analyzed by FlowJo_V10 
software.  
In vivo HCC xenograft study in nude mice 
HCC xenograft models were established by subcutaneous transplantation of Huh7 
cells into nude mice (2.5×106 cells per mouse; n = 11 mice per group). CEBPD 
knockdown cells and corresponding control cells were injected into the lower left or 
right flank of the same mice, respectively. After four weeks, mice were sacrificed and 
tumors were immediately removed and analyzed. All animal experiments were 
approved by the Committee on the Ethics of Animal Experiments of the Erasmus Medical 
Center. 
Statistical analysis 
Protein and mRNA expression of CEBPD between the HCC tumor tissues and normal 
adjacent tissues were compared using the paired Student’s t-test and the Mann–Whitney 
test. For all the functional studies, potential differences between the experimental 
groups were analyzed using a paired Student’s t-test. P < 0.05 (indicated in the figures as 
single asterisk) was considered statistically significant. P < 0.01 (indicated in the double 
asterisks) and P < 0.001 (triple asterisks) were regarded as highly significant. All 
statistical analyses were performed in GraphPad Prism 5. 
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Results 
Down-regulation of CEBPD mRNA in HCC tumors and its clinical significance  
As a first analysis of the potential clinical significance of CEBPD in HCC, we exploited 
the TGCA resource that allows analysis of transcript levels in cancers and adjacent 
tissues. We identified data on CEBPD transcript levels in primary HCC of 371 patients 
and for 50 of those also data on adjacent tumor-free liver tissue is available. An overall 
analysis of transcript levels in all HCC and adjacent tissues showed that CEBPD mRNA 
levels are significantly lower in tumor as compared to adjacent tumor-free liver tissue (P 
< 0.0001, Figure 1A) and a paired analysis of the 50 cases in which data from both 
tumor-free liver tissue as well as HCC is present of the same patients made this point 
even more clear (P<0.0001, Figure 1B). We aimed to correlate the CEBPD expression 
data to clinical descriptors such as gender, age, a history of viral hepatitis, and pathology 
grade, but no relationships emerged.  
However, we observe the link between CEBPD expression and tumor progression as 
assessed by American Joint Committee on Cancer (AJCC) staging [20]. We found that 
higher staging is associated with significantly lower CEBPD mRNA expression in tumors 
(Figure 1C). Thus clinical progression of HCC is strongly associated with lower CEBPD 
mRNA levels. Next, we investigated the relationship between CEBPD mRNA expression 
and patients’ overall survival in the TCGA LIHC cohort by Kaplan–Meier test. When 
comparing the 20% patients with the highest CEBPD mRNA tumor expression with the 
20% patients with the lowest tumor expression, we found that low CEBPD mRNA 
expression was associated with poorer survival (P = 0.043, log- rank test; Figure 1D). 
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Figure 1. CEBPD downregulation in HCC Analysis of the TCGA dataset. (A) The results show that CEBPD 
mRNA expression is significantly decreased in HCC (unpaired tissue comparison). (B) Analysis of the 
TCGA dataset. Substantial downregulation of CEBPD mRNA is observed in the comparison of paired HCC 
tumor tissue (T) and adjacent tumor-free liver (ANT). (C) Analysis of the TCGA dataset. CEBPD mRNA 
expression is related to HCC clinical staging. More advanced cancer stages are related to lower CEBPD 
mRNA levels. (D) Low CEBPD mRNA expression was associated with poorer survival in TCGA dataset. (E) 
CEBPD protein expression was determined by immunohistochemistry on tissue microarrays of HCC 
patients of the Erasmus MC (Rotterdam) and the Academic Medical Center (Amsterdam), and 
semiquantified according to the staining intensity. CEBPD protein is significantly lower in HCC tumor 
tissues compared with paired adjacent liver tissues. (F) Slides were scored on a three grade scale: weak 
(1), moderate (2) or strong (3); and for percentages of positive nuclei (<25%=1, 25%-70%=2, >70%=3). 
*P < 0.05; ***P <0 .001; ****P <0 .001. 
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Downregulation of CEBPD protein expression in HCC tumors and tumor cell lines 
To confirm that the observed downregulation of CEBPD transcripts in HCC as detected 
in our analysis of the TGCA resource corresponds to lower protein levels of CEBPD in 
HCC tumor cells (and does not derive from e.g. stromal cells), we analyzed TMAs of 
tumors of 154 HCC patients resected at Erasmus MC or AMC, and paired tumor-free liver 
tissues from 133 of these patients. We observed that lower levels of tumor cell-specific 
CEBPD protein expression in HCC tissues as compared with adjacent paired tumor-free 
liver tissues (P <0.0001, Figure 1E). In apparent agreement, when we used qRT-PCR and 
Western blot to examine the CEBPD mRNA levels and protein levels in 9 often used HCC 
cell lines and compared results to healthy human liver organoids, we observed that 
compared with healthy liver tissue, the expression of CEBPD is markedly reduced in all 
the HCC cell lines (Figure 2A and 2B). We concluded that CEBPD downregulation is an 
intrinsic property of the HCC process and initiated investigations as to test whether 
preclinical models of HCC capture this aspect of liver cancer. 
 
Figure 2. CEBPD in HCC cell lines is low when compared to normal healthy liver organoids. (A) CEBPD 
mRNA expression in HCC cell lines compared to normal healthy liver organoids. Organoids were grown in 
organoid expansion medium (Data represent mean ± SEM, n=3) (B) Western blot showing CEBPD protein 
expression in HCC cell lines. *P < 0.05; **P <0 .01 
 
Paradoxal reduction of cell proliferation and colony formation following 
knockdown of CEBPD in HCC cell lines 
To investigate whether the clinical relevance of CEBPD downregulation in HCC is 
mirrored by increased aggressiveness in in vitro models of HCC, we constructed CEBPD 
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knock down derivatives of both Huh7 and HepG2 employing an RNAi-mediated 
approach. This approach was successful in that various clones with reduced levels of 
CEBPD were created (henceforth referred to as CEBP-KD cells), especially when 
compared to cells transfected with a scrambled control vector (shCTR cells; Figure 3). 
Subsequently, the resulting clones were interrogated for overall proliferation, their 
capacity for single cell-derived colony formation as well as the effects of loss of CEBPD 
on cell cycling. We observed that CEBPD–KD cells are substantially hampered with 
respect to proliferative and colony forming potential (Figure 4A and 4B). We also 
investigated the effects of loss-of-CEBPD expression on cell cycling in these preclinical 
models of HCC, employing PI staining and FACS analysis. We found that CEBPD-KD cells 
display G0/G1 cell cycle arrest (Figure 4C). In conjunction, these results reveal a 
paradoxical inhibition of apparent pro-oncogenic behavior in CEBPD-KD cells, which 
contrasts the loss of CEBPD expression in clinical HCC and suggests that these in vitro 
models fail to capture important aspects of the HCC process. 
 
 
Figure 3. CEBPD knockdown efficiency. Knockdown was performed in (A) HepG2 cell line and (B) Huh7 
cell line and efficacy was quantified by both qRT-PCR (upper graphs, mean ± SEM, n=3) and Western Blot 
(lower figures). *P < 0.05; **P <0 .01. 
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Figure 4 CEBPD expression drives HCC compartment expansion. Depletion of CEBPD expression strongly 
inhibits cell growth and the capacity for single cell colony formation in HCC cell lines. (A) Effects od CEBPD 
KD on cell proliferation as measured by MTT assay following 7 days of culture (mean ± SEM, n=3) (B) 
CEBPD KD effects the number of single cell-derived colonies as assayed 2 weeks following seeding (mean ± 
SEM, n=6 for each clone) (C) CEBPD knockdown induces G0/G1 cell cycle arrest. Propidium Iodide 
staining is used to distinguish the different stages of the cell cycle. The faction of cells in G0/G1 is 
increased in CEBPD-depleted cells (mean ± SEM, n=5 for each clone). *P < 0.05; **P <0 .01; ***P <0 .001; 
****P <0 .0001.
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Stable lentiviral-mediated knockdown of CEBPD in HCC cell lines impairs 
tumorigenesis in vivo 
The notion that the clinical effects of downregulation of CEBPD expression in clinical 
HCC are not reflected in current pre-clinical models of disease is substantiated in 
experiments in which we used nude mouse xenografting to examine the tumorigenicity 
of shRNA-mediated CEBPD-KD cell lines. At bay with the observed negative relationship 
between CEBPD downregulation and the clinical outcome of HCC, we observed that 
CEBPD-KD cells form much smaller tumors in mice as compared to control cells (P<0.05, 
Figure 5). Subsequently, we initiated experiments as to dissect the potential mechanistic 
basis of the observed discrepancy. 
 
Figure 5. Downregulation of CEBPD inhibits HCC tumor growth in vivo. (A) A xenograft model of HCC by 
subcutaneous transplantation of Huh7 cells into nude mice was used CEBPD knockdown cells and 
corresponding control cells (2.5×106 cells per injection) were injected into the lower left or right flank of 
the same mice (n = 11), respectively. Tumor size after 4 weeks is shown. shCTR = upside; shCEBPD = 
downside) (B) Summary of tumor weights, indicating that CEBPD knockdown significantly decreases the 
tumor volume in the nude mice xenograft model (*:P=0.03) 
RNA-seq analysis of the effects of CEBPD target genes 
To provide mechanistic clues as to the effect of CEBPD downregulation, we exploited 
the GEO RNA-seq resource. Under accession number GSE69604 [21] this resource 
catalogues the effect of CEBPD-KD in MCF-7 cancer cells. A list of genes differentially 
expressed in the presence or absence of CEBPD was created based on a p-value cutoff of 
<0.05 and fold-change of >1.5 or < -1.5, and we used IPA software to establish the 
signaling pathways affected by CEBPD-KD. Also as a consequence of a cutoff Z-score ≥ 2 
only a single signal transduction category was considered relevant by IPA, in case “acute 
phase response signalling” is mapped by IPA software, and includes 11 genes (Figure 
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6A). Although the background of the cell line in this IPA analysis is non-hepatic, the 
results may indicate that difference between the clinical and pre-clinical behavior of 
CEBPD expression maybe due to a role of CEBPD in supporting acute phase response 
signaling. 
Confirmation of differential gene expression by qRT-PCR 
A potential role for acute phase response signaling in explaining the differential 
effects between clinical HCC and preclinical models was supported by experiments in 
which the effects of CEBP-KD in Huh7 and HepG2  cell lines on the expression of the 
gene products involved in acute phase response signaling was determined using 
qRT-PCR. The results demonstrate that, with the possible exception of RRAS, the effects 
of CEBPD-KD mirror those seen in the GEO resource for MCF-7 cells (Figure 6B). 
Especially expression of IL1RN (interleukin 1 receptor antagonist), ITIH2 
(inter-alpha-trypsin inhibitor heavy chain 2) and SERPINA3 (serpin peptidase inhibitor, 
clade A [alpha-1 antiproteinase, antitrypsin], member 3) are significantly reduced, up to 
50% following CEBPD-KD. Conversely, the expression level of CRABP2 (cellular retinoic 
acid binding protein 2) was doubled. We also verified that the link between CEBPD and 
interleukin 1 receptor antagonist existed in the TCGA resource liver cancer dataset 
(Spearman Score were 0.31 and 0.39; Figure 6C). Acute phase response signaling 
involves multiple cell types and its importance may only emerge in the context of 
interaction of different types of cell that may not exist in in vitro cultures are may 
require species-specific signaling. Thus the observation that acute phase response genes 
are a target of CEBPD provide a rational explanation for the difference between 
preclinical models and clinical HCC. 
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Figure 6. Effects of CEBPD knockdown on gene expression. Gene set enrichment analysis was performed 
on a differentially expressed genes identified in RNA-seq data sets (A) Pathway analysis on RNA-seq data 
(GSE69604). In this data set MCF7 cells were transfected with siRNAs against CEBPD or control siRNA). 
The blue color represents the signal pathways that are inhibited at this condition. The heat map depicts 
the differentially expressed genes and highlights the effects on the Phase Response signaling category (B) 
Differential gene expression HCC cell lines with or without CEBPD knockdown (mean ± SEM, n=4-5) (C) 
Co-expression between CEBPD and IL1RN and SERPINA3 in the TCGA dataset. *P < 0.05; **P <0 .01; ***P 
<0.001. 
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Discussion 
In line with their recognized status as a relevant family of transcription factors, all five 
C/EBP family members have been associated with altered cellular fate, including cell 
cycle arrest, differentiation [22], and apoptosis [23]. In this study, we observed that 
outcome of clinical HCC associates with reduced CEBPD expression. This fits with 
observations that in genetic murine models prone to develop mammary cancer CEBPD 
appears to act as a tumor suppressor [24] and the observations from the present study 
suggest a similar functionality of CEBPD with respect to clinical HCC as well. The failure 
of preclinical models to capture this effect appears to relate either the absence of 
interaction between different cell types for in vitro models or possibly hampered 
intracellular communication due to species differences in xenograft models. In support 
of this latter notion is also the apparent role of CEBPD in acute phase response signaling 
but this line of thinking is fostered by literature data as well, that show in glioblastoma 
CEBPD mRNA overexpression in mesenchymal cells in a manner related to adverse 
prognosis [25]. Nevertheless, a role of CEBPD as a tumor suppressor gene appears 
certainly not universal: for urothelial carcinoma, CEBPD copy number amplification and 
overexpression can be related to poor prognosis and promote tumor metastasis [26]. 
However, CEBPD mRNA expression downregulation had been found in many different 
tumor types, such as hepatocellular carcinoma [27], leukemia [28], breast cancer [29], 
cervical cancer [30], and it also can be a biomarker for predicting better survival in 
breast cancer patients [31]. Thus the status of CEBPD as a candidate tumor suppressor 
gene is strong and the present work adds to the current momentum in the field in this 
respect. 
The discrepancy between preclinical models and clinical HCC with regard to CEBPD 
probably relates to its function in inflammation [32], which although relevant for clinical 
disease course is poorly captured in current models of disease. CEBPD is well 
established to become transcriptionally active in ongoing inflammatory reactions and 
the current work shows that its downregulation is associated with loss of 
immune-related signaling. It has become clear that the immune system is an important 
disease-constraining factor in HCC [33] and one can envision that loss of CEBPB 
provokes an immune tolerant environment that enables cancer to thrive even in the 
presence of functional immunity. In support of this notion is our finding that CEBPD-KD 
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leads to upregulation of CRABP, which is well known to stimulate regulatory 
lymphocytes and may thus foster immune escape of cancers. Preclinical models that 
involve overall proliferation or colony formation obviously do not measure immune 
system involvement. Likewise, xenografting cancer cells in immunodeficient mice also 
only minorly involves the immune system. Nevertheless, the effects on compartment 
expansion of CEBPD in HCC in the absence of immune interaction are quite strong and 
the observation that CEBPD behaves in clinical HCC as tumor suppressor shows that the 
importance of immunological pressure in clinical HCC development is even larger as 
contemplated hitherto and emerges from the current studies the major force driving the 
HCC process. 
Disregarding the exact details as to the discrepancy in the effects of loss of CEBPD 
expression in clinical HCC versus the effect of CEBPD-KD in preclinical models, the 
present study has established that translation of findings obtained in often used models 
of this disease like cell proliferation, single cell colony formation and xenografting is not 
straightforward and may actually be counterproductive. As these models continue to 
form the mainstay of current HCC research, this lack of translational capacity may be a 
reason why efforts to combat this disease have been so notably unsuccessful. Thus we 
interpret the current study as a call reevaluate current models and concentrate on those 
which do involve functional interaction with the immune system. 
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Summary 
The critical components of Wnt signaling in HCC 
Hepatocellular carcinoma (HCC) is a serious malignancy associated with high 
morbidity and mortality. Aberrant activation of Wnt/β-catenin signaling has been shown 
to significantly contribute to the initiation and progression of HCC [1]. In this tumor type 
this is mainly accomplished by acquiring activating somatic mutations in the CTNNB1 
gene coding for β-catenin (20-25%), or less frequently inactivating mutations within 
AXIN1 (10%). In this thesis, I investigated how novel hotspot β-catenin variants lead to 
enhanced β-catenin signaling. In addition, I explored to what extent AXIN1 mutation 
leads to enhanced signaling in liver cancer cell lines, as this has been debated in several 
papers in the last decade. Liver cancer cell lines were also tested for their dependency on 
extracellular Wnt ligand activation to sustain their growth. Furthermore, we also 
identified STRAP as a novel protein that modulates β-catenin signaling in HCC. Lastly, I 
identified CEBPD whose expression levels appear to be associated with HCC prognosis. 
During the last decades, great progress has been made in our understanding of 
Wnt/β-catenin signaling. Especially the process of N-terminal phosphorylation in exon3 
encoded S/T residues of β-catenin and its subsequent proteolytic degradation, are 
well-understood. Mutations in this domain lead to aberrant activation of Wnt/β-catenin 
signaling activation by making the protein more resistant to proteolytic degradation 
[2-4]. 
Summary and Discussion 
173 
Except for β-catenin and AXIN1 mutation, Wnt ligands themselves are also recognized 
as factors which may promote tumor growth in a subset of tumors. Therefore, therapies 
that reduce Wnt ligand exposure to the tumor cells could be a promising option for HCC 
treatment [8]. In Chapter 4 we investigate to what extent the growth of HCC cell lines 
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(n=9) can be affected by reducing Wnt ligand exposure, taking colorectal cancer cell lines 
along as controls. First, we show that siRNA mediated knock-down of β-catenin impairs 
the growth of all HCC cell lines. Blocking Wnt secretion, either by treatment with the 
IWP12 porcupine inhibitor or knockdown of WLS, also reduces the growth of most lines. 
Unexpectedly, inhibition of Wnt secretion does not show clear changes on Wnt/β-catenin 
signaling activities, which is reflected by minor changes in neither β-catenin reporter 
activity nor the expression of a well-known β-catenin target gene AXIN2. Similar results 
were observed for colorectal cancer cell lines used for comparison in various assays.  
Our results suggest that most colorectal and liver cancers with mutations in 
components of the β-catenin degradation complex do not strongly rely on extracellular 
Wnt ligand exposure to support optimal growth. Blocking Wnt secretion may however 
aid in tumor suppression through alternative routes currently unappreciated. 
In addition to somatic mutations of Wnt signaling components, there are many other 
regulators which may affect the activation of the Wnt/β-catenin signaling pathway. In 
Chapter 5, we revealed the importance of the oncogenic serine-threonine kinase 
receptor-associated protein (STRAP) to maintain optimal levels of β-catenin signaling 
and provide growth advantage in HCC cell lines. Increased expression of STRAP was 
observed in HCC patient’s tissues, in accordance with previous studies for other tumor 
types [9-11]. For functional analysis, siRNA and CRISPR/Cas9 mediated loss-of-function 
studies of STRAP were performed on HCC cell lines, leading to inhibition of cell growth, 
cell cycle arrest and the impaired ability to form colonies. In accordance with a colorectal 
cancer study as described in the previous [12], STRAP downregulation or knockout 
significantly inhibited β-catenin target gene expression and induction of a β-catenin 
reporter system.   
In conclusion, the increased STRAP protein levels observed in HCC, provide growth 
advantage among others by affecting Wnt/β-catenin signaling. These observations also 
identify STRAP as a new player in regulating β-catenin signaling in hepatocellular 
cancers.  
Previous studies have shown that the function of CEBPD is highly linked to 
carcinogenesis and innate immune responses [13, 14], however, due to its 
multifunctional characteristics its exact role remains controversial [15]. In Chapter 6 we 
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investigate its role in HCC. Our results showed that CEBPD mRNA expression is 
significantly downregulated in HCC tumor tissues as compared to adjacent liver tissues, 
further confirmed by protein expression analysis on TMA slides. In both Huh7 and 
HepG2 cells shRNA-mediated CEBPD knockdown significantly reduces cell proliferation, 
single cell colony formation and arrests cell cycling in the G0/G1 phase. Next, by 
analyzing RNA-sequencing data of CEBPD-KD experiments in MCF-7 cancer cells, we 
performed Gene Set Enrichment analysis, which indicated that CEBPD knockdown 
indirectly enhanced interleukin-1 (IL-1) signaling by affecting IL1RN expression, which 
is a natural inhibitor of IL-1 signaling. The reduction in IL1RN levels was confirmed by 
q-PCR in our CEBPD-KD Huh7 and HepG2 cells. Subcutaneous xenografting of Huh7 in
nude mice showed that CEBPD knockdown results in smaller tumors. We conclude that 
CEBPD expression uncouples cancer compartment expansion and clinical outcome in 
HCC, potentially by modulating interleukin-1 signaling. Thus, although our results 
support the notion that CEBPD acts as a tumor suppressor in HCC, its action does not 
involve impairing compartment expansion per se but more likely acts through improving 
anticancer immunity. 
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1 mutational mechanisms of increased Wnt/β-catenin signaling in HCC 
Although the pathogenesis of HCC is multifactorial and heterogeneous, it is widely 
accepted that the Wnt/β-catenin signaling pathway is in a state of aberrant activation in 
the majority of liver cancers. In the first section of the thesis we focused on the role of 
key mutational components in the Wnt/β-catenin signaling pathway with regard to 
aberrant activation.  
The best understood mechanism for aberrant Wnt signaling is the β-catenin 
mutations that are located at exon3, which account for 20-25% of all HCC cases. They 
lead to a defect in N-terminal S/T phosphorylation or β-TrCP binding, resulting in a β-
catenin protein more resistant to proteolytic degradation and enhanced nuclear 
signaling. 
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The same argument applies to AXIN1  mutations as well, which are observed in about 
8-10% of HCCs. The last decade several papers emerged suggesting that AXIN1  mutation 
does not contribute to tumor formation by aberrantly activating β-catenin signaling. 
These statements were largely based on observing only a weak or seemingly negligible 
activation of β-catenin target genes in liver cancers, and no obvious nuclear accumulation 
of β-catenin. Apparently, many researchers still believe that only a strong induction of 
signaling efficiently contributes to tumor growth, but as explained above a weak 
activation can already provide a growth advantage depending on tissue type and context. 
it does not formerly proof that β-catenin signaling is required to sustain their growth. In 
that respect, we show in chapter 4 that CTNNB1  knock-down reduces the growth of all 
three AXIN1-mutant lines tested [22]. Recently, stronger evidence was provided by Qiao 
et al [23]. By simultaneously knocking-out Axin1  and Ctnnb1  in mouse livers, the tumors 
formed by Axin1  deletion alone could be completely prevented, showing that β-catenin 
signaling is absolutely required. 
Overall, our work highlights two mutational mechanisms leading to only a modest 
increase in β-catenin signaling that nevertheless appears to be very relevant for liver 
tumorigenesis. 
2 Therapies targeting Wnt signaling in HCC 
Due to the lack of sensitive and valid biomarkers for early diagnosis of HCC, the 
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majority of HCC patients are diagnosed at a late stage, leaving a limited number of 
treatment options. At present, for patients detected at an early stage of tumor formation, 
tumor resection and liver transplantation are the main suitable treatment options, 
resulting in a 5-year overall survival rate of only 30%-40%. For HCC patients with 
advanced disease, Sorafenib is the only treatment option, which can extend the median 
overall survival with a modest 2-3 months.  
Given the strong involvement of Wnt/β-catenin signaling in the pathogenesis of HCC, 
we have evaluated two inhibitors targeting components of Wnt signaling for their 
effectiveness in reducing the growth of HCC cell lines. The first one is IWP12 belonging 
to the class of Porcupine-inhibitors, which inhibits the secretion of Wnt ligands. The 
underlying rationale for this approach was that HCC cells may still partially depend on 
extracellular Wnt ligand exposure to sustain sufficient β-catenin signaling, especially in 
cell lines with weaker activation of the pathway, i.e. AXIN1- and non-mutant lines. Using 
this inhibitor we observe a modest but significant reduction in growth in most lines. 
Surprisingly, this was not accompanied by a clear reduction in nuclear β-catenin 
signaling, indicating that the growth inhibition was induced through other mechanisms. 
Our analysis of ER-stress and autophagy did however not provide indications that these 
mechanisms are involved. Following our publication it was shown by others that 
IWP-molecules also possess an inhibitory capacity towards Casein Kinase 1δ/ε [24]. 
These kinases are involved in regulating a large number of cellular processes, and as 
such their inhibition may have contributed to the growth inhibition that we observed. If 
true, it may also indicate an alternative method of reducing HCC growth by testing more 
specific Casein kinase inhibitors. 
The second Wnt signaling related compounds tested by us were the so-called 
tankyrase-inhibitors. Blocking tankyrase activity is expected to stabilize AXIN-proteins, 
thereby theoretically leading to a more efficient breakdown of β-catenin. Although we do 
see some inhibition of β-catenin signaling in the AXIN1- and non-mutant lines, the 
reduction is not sufficient to very effectively reduce their growth. These lines have a 
relatively low baseline expression of the AXIN proteins, which likely explains why it was 
technically difficult to show a clear accumulation of AXIN following tankyrase inhibition 
and the modest overall effect on β-catenin signaling. All three tested CTNNB1 mutant 
lines were largely resistant to tankyrase inhibition, in line with their dominant effect on 
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signaling. Overall, this analysis suggests that tankyrase inhibition is not likely to become 
an effective therapy for HCC, at least not as a monotherapy. 
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De belangrijkste componenten van Wnt signalering in HCC 
Het hepatocellulair carcinoom (HCC) is een ernstige maligniteit die geassocieerd is 
met een hoge morbiditeit en mortaliteit. Een afwijkende toename van Wnt/β-catenine 
signalering levert een belangrijke bijdrage aan de initiatie en progressie van HCC. In dit 
tumortype wordt dit voornamelijk veroorzaakt door het verkrijgen van activerende 
somatische mutaties in het CTNNB1 gen (20-25%), coderend voor β-catenine, of minder 
vaak door inactiverende mutaties in AXIN1 (10%). In dit proefschrift heb ik onderzocht 
hoe nieuw ontdekte β-catenine varianten leiden tot verhoogde β-catenine signalering. 
Daarnaast onderzocht ik in welke mate AXIN1 mutaties leiden tot verhoogde signalering 
in leverkankercellijnen, omdat hierover de laatste jaren een controverse is ontstaan. 
Leverkankercellijnen werden ook getest op hun afhankelijkheid van extracellulaire Wnt 
ligand activatie om een optimale groei te kunnen behouden. We ontdekten ook dat het 
STRAP-eiwit de sterkte van het β-catenine signaal beïnvloed in HCC. Als laatste 
identificeerden we CEBPD, waarvan de expressie-niveaus associëren met HCC prognose. 
 De afgelopen decennia is er grote vooruitgang geboekt in ons begrip van 
Wnt/β-catenine signalering. Vooral het mechanisme van N-terminale fosforylatie van 
exon3 gecodeerde S/T residuen en de daaropvolgende eiwitafbraak, wordt goed 
begrepen. Mutaties in dit domein leiden tot verhoogde β-catenine signalering doordat ze 
het eiwit meer resistent maken tegen afbraak.  
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Naast mutaties in β-catenine en AXIN1, zijn er aanwijzingen dat de Wnt-liganden zelf 
ook tumorgroei kunnen bevorderen in een deel van de tumoren. Therapieën die de 
blootstelling van tumorcellen aan Wnt liganden kunnen verminderen, zouden daarom 
mogelijk ook bruikbaar zijn voor de behandeling van HCC. In hoofdstuk 4 onderzoeken 
we in welke mate de groei van HCC cellijnen (n=9) beïnvloed kan worden door 
verminderde blootstelling aan Wnt-liganden, waarbij we darmkanker cellijnen 
meenemen ter controle. Allereerst laten we zien dat knockdown van β-catenine door 
middel van siRNA, leidt tot een verminderde groei van alle HCC cellijnen. Het blokkeren 
van Wnt-secretie d.m.v. een behandeling met de IWP12 Porcupine-remmer of 
knockdown van WLS, resulteert ook tot in een verminderde groei van de meeste lijnen. 
Deze remming van Wnt-secretie is onverwacht echter niet geassocieerd met een 
veranderde β-catenine signalering. Vergelijkbare resultaten zagen we bij 
darmkankercellijnen die we als controle hadden meegenomen. 
Onze resultaten suggereren dat de meeste darm- en leverkankers met mutaties in 
componenten van het β-catenine afbraakcomplex of β-catenine zelf, niet duidelijk 
afhankelijk zijn van extracellulaire blootstelling aan Wnt-liganden voor een optimale 
groei. Het remmen van Wnt-secretie kan echter bijdragen aan tumoronderdrukking via 
een mechanisme dat we nog niet begrijpen. 
Naast somatische mutaties in Wnt signaleringscomponenten, bestaan er diverse 
regulerende eiwitten die de activatie van Wnt/β-catenine signalering kunnen 
beïnvloeden. In hoofdstuk 5 ontdekken we het belang van het STRAP-eiwit om in 
leverkanker cellijnen een optimaal β-catenine signaal in stand te houden en hun groei te 
bevorderen. We zagen een verhoogde expressie van STRAP in levertumoren van 
patiënten, in overeenstemming met eerdere studies in ander tumortypes. Voor een 
functionele analyse gebruikten we siRNA en CRISPR/Cas9 technologieën om de 
hoeveelheid STRAP in cellijnen te verminderen of volledig uit te schakelen. Dit leidde tot 
een vermindering in celgroei, een verslechterde celcyclus en een afgenomen vermogen 
om kolonies te vormen. In overeenstemming met een darmkankerstudie, leidde verlies 
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van STRAP ook tot minder expressie van β-catenine doelgenen en inductie van een 
β-catenine reportersysteem. Samenvattend ondersteunt de verhoogde expressie van 
STRAP de groei van levertumoren onder andere door het positief beïnvloeden van 
β-catenine signalering. 
Eerdere studies hebben laten zien dat de functie van CEBPD sterk gekoppeld is aan 
carcinogenese en aangeboren immuunresponsen. Door het multifunctionele karakter 
van CEBPD blijft zijn exacte functie echter controversieel. In hoofdstuk 6 onderzoeken 
we de rol in leverkanker. We laten zien dat CEBPD mRNA expressie significant lager is in 
leverkankers in vergelijking met normaal leverweefsel. Dit wordt verder bevestigd door 
verminderde eiwitexpressie zichtbaar op TMA-coupes. Zowel in de Huh7 als ook de 
HepG2 leverkankercellijnen leidt CEBPD knockdown tot minder celproliferatie, vorming 
van kolonies vanuit losse cellen en een blokkade in de G0/G1-fase van celcyclus. Een 
analyse van beschikbare RNA-sequentie data van MCF-7 kankercellen met CEBPD 
knockdown, liet zien dat interleukin-1 (IL-1) signalering indirect versterkt werd door 
het verlagen van IL1RN expressie, een natuurlijke remmer van IL-1 signalering. 
Hetzelfde werd waargenomen in onze Huh7 en HepG2 cellen met CEBPD knockdown. De 
Huh7 cellen met verminderde CEBPD-expressie resulteren ook in kleinere tumoren na 
subcutane injectie in muizen. We concluderen dat CEBPD-expressie een loskoppeling 
geeft van de expansie van de kankercomponent en de klinische HCC prognose, mogelijk 
door het beïnvloeden van IL-1 signalering. Ondanks dat onze resultaten de rol van 
CEBPD als tumoronderdrukker in HCC bevestigen, lijkt dit niet door middel van het 
remmen van de expansie van de kankercomponent maar waarschijnlijker door het 
bevorderen van de antikanker-immuniteit. 
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